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CHAPTER I 
BACKGROUND INFORMATION 
Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disorder that irreversibly impairs cognitive 
processes, most notably in the domain of memory. AD is the most common form of dementia, 
constituting an estimated 60-80% of all dementia cases1. In 2010, roughly 4.7 million Americans 
were living with the disease, and that number has continued to increase2. It is estimated that by 
2050, 13.8 million Americans will be living with the disease2. In addition to the significant 
financial and emotional burden on patients and caregivers, the cost to taxpayers is tremendous. 
The cost of care for AD in the US in 2015 was $226 billion, 68% of which was paid for through 
Medicare and Medicaid. By 2050, that amount is estimated to rise to over $1.1 trillion3. It is 
possible for this rise to become manageable. If a treatment that delayed the onset of AD by just 
five years were found by 2025, projections show that it would save $367 billion by 20501. 
Unfortunately, of the top ten causes of death in the United States, only AD still has no way to 
prevent, cure, or significantly slow its progression. Finding a treatment for Alzheimer’s disease 
would not only benefit patients and families, it would benefit taxpayers and the economy. 
 
At the moment, only six drugs have been FDA approved for use in AD. All of the approved 
drugs are aimed only at relieving symptoms, not disease modification. From 2002-2012, 244 
drugs were registered for clinical trials, and only one drug made it to market- an abysmal failure 
rate of 99.6%4. There are several potential explanations for this failure rate. Many of these drugs 
have been developed using animal models, but a translational gap still exists between these 
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animals and human physiology. No animal model naturally develops AD pathology, and 
genetically modified animals do not fully recapitulate the widespread neuronal loss that is seen in 
humans with AD5. In addition, the majority of these drug trials were aimed at decreasing amyloid 
beta levels in the brain. Studies have shown that amyloid beta does not correlate well with 
cognitive testing, and may not be the primary cause of neurodegeneration6-8. Instead, it is 
possible that degeneration is due to the complex interplay between amyloid beta, tau, 
inflammation, cerebrovascular dysfunction, and a multitude of other factors.  Finally, many 
clinical trials recruit subjects who are already cognitively impaired, and in whom AD pathology 
may be beyond the point of reversibility. Future trials will benefit from research that has been 
designed with these limitations in mind.  
 
A task force of AD researchers from academia, industry, and federal regulatory bodies have 
established that improvements need to be made to current patient recruitment strategies in 
clinical trials9. This task force concluded that trial participants should be identified in the years 
prior to the onset of dementia. This may be done using amnestic Mild Cognitive Impairment 
(aMCI) criteria combined with one or more physiological biomarkers. We propose that the 
diagnostic criteria for aMCI may be too broad to identify the earliest cognitive symptoms of AD, 
and more sensitive tests could be developed.  
 
With that in mind, the current project has been designed to more specifically identify subtle 
changes in cognition and physiology in human subjects who are at risk for developing AD. 
Subjects in our study are middle aged (40-60 years old) because this is likely the age group in 
which pathology is beginning to form in individuals who will later be diagnosed with the 
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disease9-11. The overall goal of this study is improve the identification of subjects who may be at 
the highest risk for the development of AD, so that in the future these people may be targeted for 
treatment.  
 
For this study we have chosen to focus on three primary aims. First, to better understand how 
AD risk may influence subtle cognitive processes using behavioral tasks that have been designed 
based on a thorough understanding of early AD pathology. Second, to examine the influence of 
AD risk on markers of cerebrovascular function. Third, to determine if there is a correlation 
between cerebrovascular function and cognition, and how this relationship may differ between 
controls and at risk subjects. Any results that are discovered in the course of this work will add to 
the knowledge of physiological processes that are and are not occurring in at risk subjects 
decades before AD is diagnosed. This work may lead to better subject screening for clinical trial 
design, and/or new therapeutic targets. 
 
Alzheimer’s Disease Pathology and Progression 
The region of the brain primarily associated with AD is the medial temporal lobe (Figure 1) This 
region is comprised of hippocampal and extrahippocampal regions and it is most commonly 
implicated in the formation and storage of memories. For this project, we are particularly 
interested in the medial temporal lobe (MTL), specifically the perirhinal and entorhinal cortices, 
and the CA1, CA3, and Dentate Gyrus (DG) regions of the hippocampus.  
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There are two primary forms of pathology associated with AD: amyloid beta plaques and 
neurofibrillary hyperphosphorylated tau tangles. These pathologies follow a stereotypical route 
throughout the cerebral cortex and the medial temporal lobe. The definitive research on AD 
pathology progression was accomplished in 1991 by Braak and Braak12, who describe distinct 
stages of amyloid and tau accumulation. 
 
Amyloid Pathology 
Amyloid plaques are aggregates of the amyloid beta (Ab) peptide that develop in the brain 
parenchyma. Although the exact mechanisms by which amyloid plaques cause neural damage 
haven’t been fully characterized, soluble Ab oligomers have been shown to disrupt synaptic 
plasticity and cause synaptic loss13.  
 
The distribution of early amyloid accumulation varies among individuals, thus only three stages 
of amyloid accumulation have been described (Figure 2). In Stage A, amyloid deposits are 
observed in the basal portions of the frontal, temporal, and occipital lobe. Staining in the 
entorhinal cortex and presubiculum has demonstrated weak amyloid accumulation with ill-
defined boundaries. The hippocampus does not exhibit amyloid accumulation. In Stage B, 
amyloid deposits are evident in most of the cortex except the primary sensory and motor areas. 
Some amyloid deposition is seen in the white matter. Amyloid is present in the presubiculum and 
entorhinal cortex. Hippocampal deposits are primarily restricted to CA1, although other sectors 
may show a few deposits. In Stage C, nearly all of the cortex exhibits dense amyloid 
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accumulation, and subcortical structures are involved. The hippocampus still retains a relatively 
low level of amyloid.  
 
Tau Pathology 
Normally tau is a peptide used to create microtubules, the primary means of axonal transport. 
When tau is pathologically hyperphosphorylated it can oligomerize in the axon and physically 
prevent the transport of substances within the axon. This leads to synaptic dysfunction and 
neurodegeneration.  
 
Most individuals develop tau pathology in a highly similar way, therefore tau accumulation has 
better defined stages than amyloid pathology (Figure 3). In Stage I, tau begins to accumulate in a 
lateral region of the perirhinal cortex called the transentorhinal region14. In Stage II, numerous 
tangles are apparent in the transentorhinal region, and some are evident in the CA1 region of the 
hippocampus. In stage I and II pathology is mostly confined to the entorhinal regions and is not 
evident in the cortex, therefore these stages together are called the “Transentorhinal Stages.” In 
Stage III there is severe involvement of the transentorhinal and entorhinal regions, and modest 
involvement of CA1. Some individuals may exhibit limited tau pathology in the frontal, 
temporal, and occipital cortices and mild involvement of subcortical regions. In Stage IV, there 
is severe involvement of the entorhinal and transentorhinal regions, and numerous tangles are 
observed in the CA1. The cortex is only mildly involved, but subcortical regions are affected. 
Stages III and IV are referred to as the “limbic stages.” Stage V exhibits severe involvement of 
the entorhinal cortex and all areas of the hippocampus. Subcortical regions exhibit large numbers 
of tau. Stage V is also evidenced by the accumulation   
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Figure 2: Braak staging of amyloid pathology. In Stage A, amyloid is only 
found in basal regions of the cortex. In Stage B, amyloid is present in almost 
all cortical association areas, but absent from motor and sensory areas. The 
hippocampus is only mildy involved. In Stage C, amyloid is present in all 
cortical regions. (Figure taken from Braak and Braak 1991) 
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of tau pathology in the cortex. In Stage VI, the entorhinal regions, hippocampus, subcortical 
regions, and the cortex exhibit severe tau pathology. Stage V and VI are referred to as the 
“isocortical stages.”  
 
Vascular Pathologies 
There is some evidence that there may be a vascular component to the development of AD. 
Epidemiological studies have indicated that AD shares a number of risk factors with 
cardiovascular disease including hypertension15-17, hypercholesterolemia18,19, diabetes 
mellitus20,21, atherosclerosis22,23, smoking24, and obesity25. Post mortem studies have indicated that 
most AD brains exhibit vascular pathology such as microvascular disease, periventricular white 
matter lesions, and cerebral amyloid angiopathy26,27. Furthermore Ab interferes with vascular 
function28,29. Subjects with AD have a reported 40% lower rate of cerebral blood flow (CBF) 
compared to cognitively normal controls throughout the brain30,31, and evidence has shown that 
hypoperfusion may precede clinical symptoms32. Mounting evidence has indicated that 
cerebrovascular dysfunction may occur decades before a diagnosis. Wierenga et. al. have posited 
that there may be a biphasic curve of CBF function in AD with increased CBF early in life 
(figure 4), followed by reduced CBF as the disease advances33. A number of previous studies 
have shown that cerebrovascular reactivity (CVR), an index of vascular functionm is also 
impaired in subjects diagnosed with AD34-42.  
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Figure 3: Distribution of neurofibrillary (tau) tangles. In stages I-II pathology is 
confined to the transentorhinal region, in stage III-IV pathology severely involves 
the entorhinal regions and enters the hippocampus, and in stages V-VI pathology is 
seen in the cortex. (Figure taken from Braak and Braak 1991). 
	10	
 
 
 
 
  
Figure 4: Hypothetical model of CBF in AD. The brain is hyperperfused in the pre-clinical 
stages of AD, then becomes hypoperfused in the later stages. (Figure taken from Wierenga et. 
Al. 2014).  
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Other Pathologies 
Human and animal studies have shown a number of other pathophysiologies associated with AD, 
including neuroinflammation43, oxidative stress44, mitochondrial dysfunction45, and Ca2+ 
dysregulation46. The temporal order of events and relative contribution of each to the AD 
phenotype is still unclear.  
 
Hypotheses Regarding the Development of Alzheimer’s Disease  
For two decades, the overwhelming hypothesis regarding the development of AD was the 
Amyloid Cascade Hypothesis (ACH). This hypothesis, based on the best known biochemical, 
neuropathological, and genetic information available at the time, states that the accumulation of 
Ab is the first step in the development of AD and initiates all other pathologies. The ACH has 
fallen into criticism in recent years with some researchers suggesting that it should be abandoned 
altogether47. Autopsy studies and Positron Emission Tomorgraphy (PET) studies have indicated 
that many cognitively normal older adults have evidence of amyloid in their brains48. Clinical 
trials in which AD patients were immunized against Ab were halted due to adverse events, but 
the patients whose plaque burdens were successfully reduced during the trial did not show any 
improvements in their cognitive symptoms7.  These data indicate that amyloid pathology is 
neither necessary nor sufficient for the cognitive symptoms of AD. 
 
AD may also be characterized as a primarily tau-based disease. As previously mentioned, tau 
pathology follows a more stereotypical route through the brain than amyloid pathology49. Tau 
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pathology precedes amyloid pathology50,51 and is more closely correlated with neuronal loss than 
amyloid, both spatially and temporally52. Studies have shown that tau pathology also correlates 
more strongly with cognitive function than amyloid pathology53. Tau may be a better target for 
understanding the earliest stages of AD than amyloid. Studying tau in humans in vivo has been 
limited because until recently tau could only be detected using a lumbar puncture, which limits 
spatial information, or after death. A PET ligand for tau is currently being developed54 that will 
help elucidate its spatial and temporal properties in the early stages of AD. 
 
Despite the evidence of a vascular component to AD, it is unclear whether vascular or amyloid 
pathology arises first. The two-hit theory of AD posits that some vascular insult (the first hit) 
which may be related to aging or vascular risk factors results in changes to the blood brain 
barrier and hypoperfusion. This contributes to the production, accumulation, and impaired 
clearance of Ab (second hit), which ultimately leads to the tissue damage and dementia 
associated with AD55. Lending support to this theory is the observation that in transgenic mice 
overexpressing the Swedish mutation of the gene for amyloid precursor protein (App) 
cerebrovascular dysfunction develops earlier than cognitive changes and Ab plaque 
formation56,57.  
Role of Family History, Aging, and Genetics on Disease Risk 
In order to better understand the earliest stages of AD pathology, we must look at people who are 
likely to develop the disease in the future decades before a diagnosis can currently be made. Risk 
of AD increases with age, and most people who are diagnosed with AD are over 65 years old1,2, 
therefore we chose to study middle aged subjects between 40 and 60 years old.  
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Family history of AD also increases risk for the disease, and may be the largest determinant of 
overall risk. Heritability of AD was estimated at approximately 58%, and people who have a first 
degree family history of AD have 2-4 times the lifetime risk as people with no family history58. 
Therefore, the primary characteristic we used to stratify subjects into “At risk” and “control” 
groups was family history.  
 
Researchers have worked to identify specific risk genes that contribute to the development of 
AD, and genome-wide association studies have identified over 100 genes that may confer AD 
risk58. The most common risk gene for AD is a cholesterol-processing gene called apolipoprotein 
E. There are three possible isotypes of Apolipoprotein, e2 (ApoE2), e3 (ApoE3), and e4 
(ApoE4). Most of the general population (60%) has two copies of ApoE3, however, 23% of the 
population is estimated to carry one or two copies of ApoE459. This gene has been associated 
with an increased incidence of AD, a decreased age of onset, and reduced survival60. An alternate 
allele of apolipoprotein, e2(ApoE2) has been identified as a protective gene for the development 
of AD61. Subjects were genotyped for Apolipoprotein E to further assess their overall risk of AD. 
 
Summary 
AD is a devastating disease and a growing public health risk. In order to combat the anticipated 
rise in AD rates, patients with AD need to be identified as early as possible. This study aims to 
identify the earliest cognitive and physiological features of AD by intensely examining subjects 
at risk for AD.  
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CHAPTER II 
STUDY OVERVIEW AND SUBJECT CHARACTERISTICS 
Specific Aims and Hypotheses 
This study had three primary hypotheses: 
 
 
Hypothesis 1: Middle-aged individuals at risk for AD will have reduced performance on 
sensitive cognitive tests of MTL function compared to age-matched controls. 
Aim 1: MTL function of middle aged at risk subjects and age-matched controls will be examined 
using cognitive tests that target specific subregions of the MTL. These tests have been designed 
to follow the route of AD pathology progression, beginning in the entorhinal cortex (oddity 
detection), continuing into the CA1 region of the hippocampus (face-name association memory 
and object-place association memory), and moving into the dentate gyrus and CA3 (pattern 
separation). We hypothesize that performance differences between groups will follow the 
trajectory of AD pathology. In this scenario, we hypothesize that the first task to be affected 
would be the oddity detection task.  The second task would be the associational memory tasks, 
and the third task would be pattern separation. We predict that there will be no differences in 
groups in associational memory or pattern separation if there are no differences in oddity 
detection. Standard experimental data (e.g., accuracy, reaction time, etc.) from this aim will also 
be used for correlational analyses in Aim 3. 
 
Hypothesis 2: Middle-aged individuals at risk for AD will have increased CBF and reduced 
CVR in the MTL/hippocampus area compared to age-matched controls.  
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Aim 2: CVR as well as CBF and volume will be quantified in middle-aged adults at risk for AD 
and age-matched controls using arterial spin labeling (ASL) combined with a vasoactive gas 
challenge. We expect increased CBF and decreased CVR in at risk subjects compared to controls 
in the entorhinal cortex and hippocampus, but not in a region unaffected by AD, the occipital 
lobe. Most studies to date have either investigated whole brain CBF or have registered blood 
flow maps to a standard atlas for regional analysis. However, these methods may suffer from 
inaccurate registration due to individual volume differences, particularly in our population of 
interest. Importantly, we plan to use established algorithms and manual segmentation techniques 
to outline regions of interest (gray matter, hippocampi, entorhinal cortices, and occipital lobe) 
individually for each subject.  CBF and CVR values will also be used for correlational analyses 
in Aim 3.  
 
Hypothesis 3: CVR and CBF will correlate with performance on MTL-targeted cognitive 
tasks 
The data collected in Aim 1 and Aim 2 will be drawn from the same pool of subjects. 
Correlations between CVR and cognitive testing scores from Aim 1 will be calculated. These 
correlations will be separately investigated in at risk subjects and control subjects to determine if 
these relationships differ with risk for AD.  
 
Subjects 
Recruitment Goals 
We aimed to recruit a total of 75 subjects: 50 subjects with a first degree family history of AD 
(“At Risk”) and 25 subjects with no known family history of AD (“Control”). We anticipated 
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that after genetic testing, the at risk group would be divided roughly equally into carriers and 
non-carriers of ApoE e4, thus creating three groups: at risk subjects with ApoE e4 (n~25), at risk 
subjects without ApoE e4 (n~25) and control subjects (n=25) 
 
Recruitment and Screening 
Subjects were recruited through mass email lists, ResearchMatch.org, the Vanderbilt Memory 
and Alzheimer’s Center, and word-of-mouth. After initial contact, subjects answered a series of 
questions to determine eligibility for the study based on the inclusion and exclusion criteria 
(Table 1). If a subject was deemed eligible, he or she provided informed consent according to the 
Vanderbilt University Institutional Review Board. A total of 76 subjects were recruited; 47 who 
had a parent diagnosed with AD and 29 who did not. Several subjects were removed from the 
study due to abnormal performance in neuropsychological testing (n=19), incompatibility with 
the MRI (n=2) or because they no longer wished to participate (n=2). A total of 55 subjects 
completed the study. 
 
 Inclusion Criteria 
 
Male and female subjects were recruited who were between the ages of 40 and 60 years old, 
spoke English fluently, and demonstrated no cognitive impairments on standard tests of 
neuropsychological functioning.  
 
Exclusion Criteria 
 
Subjects were excluded from the study if they were knowingly unable to do all three study 
sessions, had a history of traumatic brain injury, stroke, transient ischemic attack (TIA), 
degenerative or neurological disease, psychiatric illness or mood disorder, a diagnosed learning 
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disability, uncorrected vision (<20/30), colorblindness, hearing problems, a history of alcohol or 
substance abuse, or any MRI contraindications. Subjects were asked to indicate the medications 
that they were on and were excluded if they were on anticonvulsants, antipsychotics, 
benzodiazepines, psychostimulants, opioids, tricyclic antidepressants, some norepinephrine 
reuptake inhibitors. Subjects could not be pregnant or have need for continuous oxygen, nor 
could they have respiratory disease, chronic angina, or any other unstable cardiac condition.  
 
 
Demographic Data  
Subjects were asked to self-report age, sex race, ethnicity, and years of education. Due to the 
vascular component of this study, subjects were also asked to self-report history of heart disease, 
sleep apnea, diabetes (type 1 or 2), recent smoking history and lifetime smoking history, 
medication, and estimated exercise frequency. Body Mass Index (BMI) was calculated using 
subjects’ self-reported height and weight. Subjects’ handedness was determined using the 
Edinburgh Handedness Scale.  
 
Neuropsychological Tests 
To make sure that subjects were cognitively normal for his or her age, subjects underwent a 
battery of neuropsychological testing. The battery included the Mini-Mental State Exam, the 
Logical Memory Exam (immediate recall, delayed recall, and recognition) from the Delis-
Kaplan Executive Function System (DKEFS), the Rey-Osterrieth Complex Figure Test (copy, 
immediate recall, and delayed recall), DKEFS verbal fluency (letter fluency and category 
fluency), Trails A and B, the Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD) word list learning task, the Benton Judgment of Line Orientation Test, and the Boston 
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Naming Test. Any subject who scored >1.5 standard deviations outside the norms in any test was 
removed from the study.  Subjects were also given the Beck Depression Inventory to rule out 
mood disorders.  
 
Apolipoprotein E Genotyping 
Apolipoprotein E e4 (ApoE4) is the most common risk gene for Alzheimer’s disease59 and we 
anticipated that the At Risk group would have more carriers of ApoE4 than the control group. 
Subjects were genotyped for carrier status of Apolipoprotein E (e2, e3, e4).  Buccal cells were 
collected from each subject (Oragene Discover OGR-500 kit, DNA Genotek Inc., Ottowa, ON, 
Canada) and DNA was isolated and genotyped by Vanderbilt Technologies for Advanced 
Genomics using Applied Biosystems Taqman 7900 HT Instrument (Life Technologies, Grand 
Island, NY, USA) with primers to rs7412 and rs429358.  
 
Study Timeline 
If a subject expressed interest in the study, he or she was first given information about the study 
and asked a series of questions to determine eligibility (pre-screening). Following pre-screening, 
subjects were asked to attend three separate study sessions. The first session was approximately 
one hour. During this session informed consent was obtained, demographic data was collected, 
and subjects underwent a rigorous battery of neuropsychological testing. The second session 
lasted approximately one hour and involved an MRI scan. The third session lasted approximately 
three hours during which subjects completed cognitive tasks designed to challenge different 
regions of the medial temporal lobe. All sessions for this study were completed within three 
months of initial screening. 
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Not all subjects completed each cognitive and/or neuroimaging test, therefore demographic, 
neuropsychological, and genetic results are reported separately for each of the following 
chapters. 
 
 
 
 
  
Figure 5: Timeline of study  
Pre-screening 
(10 minutes)
••Phone call or email 
verifying subject 
qualified for the study
Session 1 
(1 hour)
••Demographic data 
collection
••Neuropsychological 
testing
Session 2 
(1 hour)
••MRI session
••Genetic data 
collection
Session 3 
(3 hours)
••Cognitive testing
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CHAPTER III 
COGNITIVE TESTING REFLECTS THE ROUTE OF ALZHEIMER’S 
DISEASE PATHOLOGY 
Introduction 
 
While there are many cognitive tests that have been developed to study AD, most of these tests 
were developed to detect gross impairment due to stroke, trauma, or large lesions. The clinical 
standards are broadly based on cognitive function rather than a thorough understanding of the 
underlying anatomy of AD pathology. For this study, we proposed that creating anatomically 
targeted cognitive tasks could more fully elucidate the cognitive functions that are impacted by 
the very earliest stages of AD. 
 
Amyloid pathology varies widely among AD patients, however tau pathology follows a 
stereotypical route through the brain49. According to Braak and Braak’s staging it begins in the 
perirhinal (transentorhinal) and entorhinal cortices and presubiculum, moves to the CA1 region, 
and finally enters the CA3 region and dentate gyrus. It is only in the final stages of AD that tau 
pathology enters the isocortex. We chose to use a battery of cognitive tasks that are sensitive to 
1) the perirhinal cortex (PRC), 2) the CA1 region of the hippocampus, and 3) the CA3 and 
dentate gyrus regions of the hippocampus. We anticipated that the order of changes that we 
would see in these tasks would reflect AD pathology, i.e. we would first see changes in tasks 
targeted to the perirhinal cortex. If there was a difference between subject groups in that task we 
may see a difference between groups in tasks targeted to the CA1 region, and if that were true we 
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would then see differences in tasks targeted to the CA1 region and dentate gyrus. We would not 
anticipate that these differences would occur in a different order. 
 
Perirhinal Cortex Task 
The PRC is involved in visually processing complex objects. According to the perceptual 
mnemonic/feature conjunction (PMFC) model of Bussey and Saksida, the PRC is critical for 
combining complex features of an object into a unified representation, and any PRC 
abnormalities would result in difficulty distinguishing complex objects while leaving memory 
and lower level visual processes relatively intact62. One way to probe the function of the PRC is a 
task known as oddity detection63. In this task, subjects are asked to identify the “odd man out” 
from several perceptually similar items. Previous work has shown that damage to the PRC 
results in a reduced ability to distinguish similar complex objects, while damage to the 
hippocampus results in a reduced ability to distinguish similar scenes64,65. This deficit is 
particularly notable when the objects to be compared contain a high degree of feature ambiguity, 
and when subjects are shown unfamiliar objects such as Greebles63. Because the PRC is 
associated with the comparison of features within a single item62,65,66, we hypothesized that at risk 
subjects would be impaired at distinguishing perceptually similar stimuli featuring a single object 
(faces, familiar objects, and Greebles) compared to controls. 
 
Some studies have hypothesized that it may be possible to measure binding capacity in subjects 
using eye-tracking64. Based on this theory, subjects who are able to bind more features of a 
complex visual object will spend more time looking at a single item before comparing it to the 
next item. This is referred to as a higher number of fixations within an object area. Subjects who 
bind fewer features will spend more time looking from one object to another and back. This is 
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referred to as a higher amount of fixations between object areas. The ratio of within item 
fixations and between-item fixations, or the within-between ratio (WBR) is an index of binding 
capacity (Figure 6) 
 
 
 
 
  
Figure 6: Within-between ratio. Subjects who bind more features will 
spend more time looking within an object (a) while subjects who bind 
fewer features will spend more time looking between objects (b). 
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CA1 Tasks 
One of the roles of the CA1 is binding information together in memory67. For example, 
associating a name with a face. We chose to approach testing the CA1 in two different ways: 
face/name/occupation (FNO) memory, and object/place (OP) memory.  
 
FNO memory has been shown to be impaired in subjects with aMCI and AD. In particular, it is 
notable that the association between faces and names is often more impaired than the association 
between faces and occupations68. Performance on an FNO task has been shown to correlate with 
amyloid load in cognitively normal subjects69. We anticipated that subjects at risk for AD would 
be impaired on the face/name component of FNO, but not the face/occupation component. 
 
One of the most common complaints heard in the memory clinic is that subjects forget where 
they put everyday objects, for example forgetting where they put their keys. While there have 
been impairments observed in OP memory in aMCI patients70, most tasks involve subjects 
remembering the location of objects on a screen. We thought that it would be interesting to see 
how subjects’ memory was impacted by having control over where the objects were placed on 
the screen. By giving the subjects the option of where to place the objects, we were more fully 
replicating the real world experience of object/place memory. We anticipated that subjects at risk 
for AD may have more trouble remembering where they had placed the objects than controls.  
 
CA3 and Dentate Gyrus Tasks 
One of the functions of the CA3 and dentate gyrus (DG) is to perform pattern separation, i.e. to 
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create a unique memory for similar, but different objects.  In a pattern separation task subjects 
are shown a series of objects. After a delay, subjects are shown objects that are either novel, 
repeated, or visually similar lures, and asked to describe them as “old,” “new,” or “similar.” 
Novel objects have never been seen before, repeated objects are identical to the first presentation 
of the object, and lure objects are visually similar to an object that was previously presented, but 
not identical. An example of correct pattern separation would be responding “similar” to a lure, 
while an example of incorrect pattern separation would be responding “old” to a lure. We refer to 
incorrect pattern separation as “pattern completion,” but note that the term is used in other 
contexts to describe retrieving an intact memory from a degraded cue. Pattern separation has 
been shown by our lab and others to be impaired with aging and in subjects with aMCI and 
AD71,72. We predicted that subjects at risk for AD would demonstrate impaired pattern separation.  
 
Methods 
Subjects  
 
Methods for recruitment and screening, demographic data collection, neuropsychological data 
collection, and genetic data collection are described in Chapter II. 
 
Oddity Detection 
Participants’ primary task was to identify the “odd man out” from four visually similar items, i.e. 
the one item (target) that was different from the other three (foils). Four sets of stimuli were used 
for this task: faces, objects, Greebles, and scenes. The faces, objects and Greebles were drawn 
from the TarrLab database (courtesy of Michael J. Tarr, Center for the Neural Basis of Cognition 
and Department of Psychology, Carnegie Mellon University, http://www.tarrlab.org/. Funding 
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provided by NSF award 0339122.)  Additional objects were drawn from the Amsterdam Library 
of Object Images73. Scene stimuli were photographs taken in the Nashville area.  
The stimuli for each category were organized into pairs according to visual similarity with one 
member of the pair acting as the target item and the second member acting as the foil. The use of 
each pair member as the target stimulus was counterbalanced across participants. For faces, 
objects and scenes, visual similarity was subjectively judged by the authors and the foil was 
presented from three different viewpoints. The Greeble pairs were members of the same ‘family’ 
and ‘gender’, and each target Greeble was presented with three rotations of the foil Greeble on 
each trial (Figure 6). Rotations were randomly assigned as 0°, 90°, 180°, or 270°, with a unique 
rotation for each of the four Greebles within a single trial. All stimuli images were scaled to 
300x300 pixels. 
The on screen position of the target item was randomized for each trial.  Beneath each item was a 
digit (1, 2, 3, or 4) (Figure 6). Participants verbally reported the digit that corresponded to the 
item they believed to be the target to the experimenter, who then entered the response. 
Participants performed four blocks each consisting of a different stimulus set. For faces and 
Greebles there were 32 trials per block and for objects and scenes there were 28 trials per block. 
The order of the blocks was partially counterbalanced across participants using a Latin Square 
routine.  
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Figure 7. Example of one trial of oddity detection. Subjects were asked to state the 
number below the item that was different from the other three. In this example, the 
correct answer is 3.  
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During the task, eye tracking data was collected using an EyeLink 1000 tracker (SR Research 
Ltd., Ontario, Canada) at a sampling rate of 250 Hz. Saccades were defined as any movement of 
at least 0.1 degree visual angle (°) that exceeded a velocity threshold of 30°/s and an acceleration 
threshold of 8000°/s2. Blinks were periods of activity with missing pupil data that exceeded 3 
consecutive samples. Fixations consisted of all other recordings. The data were filtered such that 
fixations that were not on one of the four stimuli were removed from the analysis. The within-
between ratio was defined as the number of fixations within a single item divided by the number 
of fixations between items64.  Each trial began with a small dot at the center of the screen used as 
a drift correction stimulus. When the participant’s fixation to the dot was satisfactory, the 
experimenter triggered the onset of the target item and three foil items positioned in the four 
quadrants of the screen. 
 
The stimuli were displayed on a flat screen monitor (1024×768 pixel resolution, 75 Hz refresh 
rate) using Experiment Builder (SR Research Ltd.). Participants were seated comfortably in a 
chair with their heads on a chin rest that was positioned such that their eyes were approximately 
57 cm away from the monitor. 
 
Face/Name/Occupation Memory 
The Face/Name/Occupation study protocol was adapted from Amariglio et. al. 201268 Subjects 
were shown a series of 32 black and white pictures of neutral faces. First, subjects were asked to 
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observe the faces and try to identify any distinguishing characteristics, in order to familiarize 
themselves with the faces. After the subject had seen all 32 faces, they were shown the faces a 
second time, but this time a name and a job were displayed underneath each face. Subjects were 
asked to remember both the name and the job that went with each face. In both the 
familiarization and encoding stages, the faces were presented for 3 seconds. Between faces a 
white “+” would appear on the screen for 1 second. 
 
Following a delay of approximately 10 minutes, subjects were shown all of the faces again, but 
this time each face had either two names or two jobs listed below. The subjects were asked to 
identify which name or job had gone with the face earlier (Figure 7). The number of total correct, 
names correct, and jobs correct were analyzed as well as reaction times for each category. 
 
Object Place Memory 
Object place memory was assessed using an internally developed protocol. Subjects were shown 
a picture of a common household room on a computer screen (kitchen, bathroom, bedroom, etc.). 
Subjects were presented with a common household object semantically appropriate for the room 
(spoon, floss, alarm clock, etc.), and asked to use the computer mouse to place this object 
wherever they think it should go (Figure 9). Only one object appeared on the screen at a time. 
There were a total of 32 scenes and 128 objects to be placed. Following a ten-minute delay, 
subjects were presented with the same scenes and the same objects and asked to place the object 
in the same exact location that s/he placed it earlier. Subjects were scored primarily on accuracy 
(placement within 100 pixels of original placement), however on incorrect trials subjects were 
also scored on distance from original placement.  
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Figure 8: Face/Name/Occupation Memory. Subjects were first familiarized with the faces, 
then shown faces with a name and job listed below. Following a 10-minute delay subjects 
were shown the faces again, but with either two names or two jobs below the face. Subjects 
were asked to select which name or job had been presented with that face earlier.  
	30	
 
 
 
 
 
  
Figure 9: Object place task. Subjects were presented with a real world scene and an object 
and asked to place the object anywhere in the room that they wanted. Following a delay, 
subjects were given the same room and object and asked to put it in the same location they 
had earlier. If the object was placed more than 100 pixels from the original placement it was 
considered incorrect, and the distance from the original placement was recorded. 
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Pattern Separation 
Pattern separation was adapted from a paradigm developed in-house, detailed methods can be 
found in Ally et. al. (2013)72. Briefly, subjects were shown a series of real-world objects and 
asked to determine if the object would fit in a shoebox or not. Following a delay of 
approximately 10 minutes, subjects are shown a series of objects (Figure 9). One third of the 
objects was identical to objects that were shown earlier (“Repeated”), one third of objects was 
not shown before (“Novel”) and one third of objects was visually similar, but not identical to 
objects shown earlier (“Lure”). Subjects are asked to determine if the object is old, new, or 
similar.  
 
Table 1 represents the various item types and responses and what they mean. The primary 
analyses were focused on rates of bias-corrected pattern separation (pattern separation rate – 
similar bias rate) and the bias corrected pattern completion score (pattern completion rate – false 
alarm rate). 
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Figure 10: The pattern separation task. Subjects were shown real-world color objects and asked 
to determine if they would fit in a shoebox or not. Following a delay, subjects were again 
shown objects, but this time were asked to endorse the item as “old,” “new,” or “similar.” 
Correctly responding “Similar” to a lure item is pattern separation, and incorrectly responding 
“old” to a lure item is pattern completion, 
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 Response 
Item Type “New” “Similar” “Old” 
Novel Correct Rejection 
Rate 
Similar bias rate False alarm rate 
Lure Incorrect Pattern separation 
rate 
Pattern completion 
rate 
Repeated Miss rate Incorrect Hit rate 
 
  
Table 1: Pattern separation item types and responses. Bias-corrected pattern separation is defined 
as pattern separation rate – similar bias rate, and bias-corrected pattern completion rate is defined 
as pattern completion rate – false alarm rate. 
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Results 
 
Subjects 
 
A total of 34 subjects with a family history of AD (“At Risk”) and 23 subjects with no family 
history of AD (“Control”) completed the study. Subjects were matched on age, sex, race, and 
education (Table 2). As expected, the at risk group had more ApoE4 carriers than the control 
group (p=0.002). 
 
Neuropsychological Testing 
 
All subjects were cognitively normal at the time of testing, i.e. they did not score > 1.5 S.D. 
below the expected range of scores for his or her age. Subjects did not significantly differ on any 
neuropsychological test (Table 3), although there was a trend toward a difference in the memory 
portions of the Rey-Osterrieth Complex Visual Figure Test (immediate recall p=0.05, delayed 
recall p=0.08). 
 
Oddity Detection 
 
A correct trial was defined as a trial where the subject correctly identified the target item. The 
proportion of correct trials were subjected to a mixed-design repeated measures ANOVA with a 
within-subject factors of Stimulus Type (faces, scenes, objects, and Greebles) and a between-
subject factor of Group (at risk and control) (Figure 2). This analysis showed a main effect of 
Stimulus Type (F(3,56)=13.8, p<.001) and an interaction of Group and Stimulus Type(F(3,156)=3.8, 
p=.01), but no main effect of Group (F(1,52) =0.174, p=.68). After further analysis of the 
interaction using independent t-tests, a significant difference between groups was found in the 
Greebles condition (t(52)=2.28, p=0.03). When data was re-analyzed with a within-subject factor 
	35	
of Stimulus Type (faces, scenes, objects, and Greebles) and a between subject factor of ApoE4 
Carrier Status (carrier and non-carrier), we did not find an interaction of Carrier Status and 
Stimulus Type (F3,150=0.111, p=0.954) or a main effect of Carrier Status (F1,50=0.073, p=0.788). 
 At Risk 
 (n=34) 
Control  
(n=22) 
p-value 
Age (yrs ± s.d.) 53 ± 6 53 ± 6 0.888 
Sex (% female) 79 59 0.104 
Race (% non-white) 6 18 0.151 
Education (yrs ± s.d.) 17 ± 2 18 ± 4 0.077 
ApoE4 Carrier (% carrier) 63 18 0.001** 
 
 
  
Table 2: Demographic data. There were no significant differences 
between groups in age, sex, race, or education, although there was a 
trend toward a difference between groups in education (p-0.08). 
There were significantly more ApoE4 characters in the at risk group 
(p=0.001). 
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At Risk (n=34)  
Mean (SEM) 
Control (n=22)  
mean (SEM) 
p-value 
MMSE 29.88 (0.06)  29.8 (0.1) 0.34 
LM-I 29 (1) 28 (1) 0.63 
LM-D 24 (1) 24 (1) 0.89 
LM-R 26.3 (0.4) 26.4 (0.4) 0.84 
REYO-C 34.9 (0.2) 35.2 (0.3) 0.48 
REYO-I 21 (1) 23.6 (0.9) 0.07 
REYO-D 21 (1) 23.3 (0.9) 0.09 
FAS 43 (2) 48 (3) 0.19 
CAT 58 (2) 61 (2) 0.30 
Trails A 26 (1) 26 (1) 0.29 
Trails B 56 (2) 60 (2) 0.19 
CERAD-I 24.1 (0.5) 25.0 (0.6) 0.28 
CERAD-D 7.9 (0.3) 8.5 (0.3) 0.15 
CERAD-R 9.85 (0.07) 9.91 (0.06) 0.60 
JLO 23.9 (0.7) 25.4 (0.9) 0.21 
BNT 57.3 (0.5) 57.4 (0.7) 0.90 
Tower 480 (32) 476 (35) 0.93 
 
 
  
Table 3: Neuropsychological testing. There were no significant differences between groups in 
any of the neuropsychological tests. MMSE = Mini Mental State Exam, LM-I = Delis Kaplan 
Executive Function System (DKEFS) Logical Memory Test Immediate Recall, LM-D = DKEFS 
Logical Memory Test Delayed Recall, LM-R – DKEFS Logical Memory Test Recognition, 
REYO-C = Rey Osterrieth Complex Figure Test (REYO) Copy, REYO-I = REYO Immediate 
Recall, REYO-D = REYO Delayed Recall, FAS = DKEFS Verbal Fluency, CAT = DKEFS 
Semantic Fluency, CERAD-I= Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD) Word List Learning- Immediate Recall, CERAD-D = CERAD Word List Learning 
Delayed Recall, CERAD-R = CERAD Word List Learning Recognition, J-LO = Benton 
Judgment of Line Orientation, BNT = Boston Naming Test, Tower = DKEFS Tower Test  
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Several subjects reported that it was difficult at the beginning of the Greebles condition to know 
what details to look for, but after a number of trials it became easier. We wanted to determine if 
there was indeed a learning effect in this condition and, if so, whether the two subject groups 
demonstrated different rates of learning. To accomplish this, accuracy data from the Greebles 
condition was split into tertiles for each group (Figure 3) and subjected to a mixed-design 
repeated measures ANOVA with a within-subject factor of Tertile (first tertile, second tertile, 
and third tertile) and a between-subject factor of Group (at risk and control). There was a main 
effect of Tertile (F(2,90)=6.50, p<0.01) and of Group (F(1,45)=6.30, p=0.02).  However there was no 
interaction (F(2,90)=0.45, p=0.64). This indicates that there was a learning effect in both groups, 
and although at risk group was consistently less accurate than the control group, the two groups 
did not learn at different rates.  
 
Eye tracking was used to determine if there were any behavioral differences in viewing behavior, 
specifically a difference in the within-between ratio (WBR). A repeated measures ANOVA was 
performed with a within-subjects factor of Stimulus Type (faces, scenes, objects, and Greebles) 
and a between-subjects factor of Group (at risk and control). The ANOVA revealed a main effect 
of Stimulus Type (F(3,156)=203.5, p<.001) with Greebles showing the highest WBR followed by 
scenes, faces, and objects. There was a trend towards a main effect of Group (F(1,52)=3.0, p=0.09).  
However, there was no interaction between Stimulus Type and Group (F(3,156)=0.87 p=0.46). This 
indicates that, although not significant, there is a trend toward at risk subjects having a lower 
binding capacity than control subjects. Further investigation into this binding capacity is 
warranted. When data were reanalyzed with a within-subjects factor of Stimulus Type (faces, 
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scenes, objects, and Greebles) and a between-subjects factor of ApoE4 Carrier Status (carrier or 
non-carrier) we found no interaction between Stimulus Type and Carrier Status (F3,150=0.824, 
p=0.483) or a main effect of Carrier Status (F1,50=1.708, p=0.197). 
 
Face/Name/Occupation Memory 
 
The primary outcome measure of the FNO task was name accuracy and occupation accuracy. 
Performance in FNO was non-parametric, so a Mann-Whitney U test was used to test name and 
occupation accuracy separately. There was no difference between groups in name accuracy 
(Z=0.29, p=0.77), but there was a significant difference between groups in occupation accuracy 
(Z=-2.34, p=0.019). There were no differences between groups in total accuracy (Z=0.71, 
p=0.48) or reaction time (name: z=0.50, p=0.62 occupation: Z=0.65, p=0.51 total: Z=0.03, 
p=0.97). When subjects were classified based on carrier status of ApoE4 rather than family 
history of AD, there were no significant differences between groups in name accuracy (Z=0.247, 
p=0.80), occupation accuracy (Z=0.027, p=0.98), or total accuracy (Z=0.255, p=0.80).  Using a 
paired student’s t-test, we found that performance on face/name memory was worse than 
face/occupation memory for all subjects (t(55)=7.54, p<0.0001). 
 
Object/Place Memory 
 
There were no differences between groups in object place accuracy (t(52)=0.79, p=0.44). There 
were also no differences in all distances from the target (t(52)=1.11, p=0.27) or incorrect 
distances from the target (t(52)=0.34, p=0.74). Finally, there were no differences in reaction 
times between groups (t(52)=0.087, p=0.93). When the groups were divided based on ApoE4 
carrier status rather than family history we found no differences between groups in object place 
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accuracy (t(50)=1.34, p=0.19), distances from the target (t(50)=1.07, p=0.29), incorrect distance 
from the target (t(50)=1.46, p=0.15), or reaction time (t(50)=0.53, p=0.60). 
 
 
Pattern Separation 
 
There were no statistically significant differences between groups in bias-corrected pattern 
separation (t(54)=0.70, 0.49) or bias-corrected pattern completion, although there was a trend 
toward a difference (t(54)=1.56, p=0.13). There were also no differences between groups in 
overall accuracy (t(54)=0.11, p=0.91). When groups were divided based on carrier status of 
ApoE4, we found no significant differences between groups in bias-corrected pattern separation 
(t(52)=0.047, p=0.96) bias-corrected pattern completion (t(52)=1.27, p=0.21), or overall 
accuracy (t(52)=0.79, p=0.43). 
 
 
Discussion 
 
Current neuropsychological testing fails to identify individuals with AD until pathology is 
relatively advanced and likely irreversible. Research has shown that AD pathology is present in 
the brain decades before most diagnoses, and this pathology is likely disrupting neuronal 
function in subtle ways51. The goal of this study was to determine whether more sensitive and 
specific cognitive testing would recapitulate the route by which tau pathology is known to 
infiltrate the MTL, i.e. beginning in the entorhinal and perirhinal cortices, then entering the CA1, 
and finally entering the CA3 and dentate gyrus. We accomplished this by using anatomically-
designed cognitive tests targeted to each of these areas. 
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Oddity Detection 
 
Previous studies have shown that the perirhinal cortex is involved in distinguishing stimuli with 
complex visual features within a single item (i.e., faces and objects), while the hippocampus is 
involved in the perceptual processing of scenes. We did not see a difference between the groups 
with respect to performance in scenes, indicating that it is possible that if there is early AD 
pathology in the at-risk group, hippocampal functioning has been left intact. While we did not 
observe a difference between groups in real world objects or faces, we did see a modest 
difference in the processing of Greebles. One reason for this may be the relative novelty of 
Greebles compared to objects and faces. Work done in humans, monkeys, and rats have shown 
that perirhinal neurons preferentially fire in response to novel objects74,75. Human subjects with 
damage to the perirhinal cortex perform worse on this task as feature ambiguity within items 
increases. Of the stimuli that were used, subjects reported that the Greebles contained the highest 
degree of feature ambiguity, which may further explain why this stimulus in particular showed 
an effect between groups. 
 
There was an element of learning to this task, and an argument could be made that the at risk 
subjects simply took longer to learn the task than control subjects.  However, this was not the 
case. Both groups became more accurate with time, indicating that there is a learning effect to 
this task. The at risk group consistently remained less accurate across time compared to the 
control group, but learned at a similar rate. 
 
Unlike the other stimuli, the Greebles required mental rotation of the images both around the x-
axis (the object remained in the same upright orientation but was rotated left or right) and along 
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the z-axis (the object was turned 90° or 180° from the upright orientation). Many studies have 
suggested that the more an object needs to be mentally rotated for a task, the higher the neural 
activity observed76-78. Mentally rotating an object 180° may require more mental effort than 
rotating it laterally, so it is possible that this extra effort may influence performance in this task. 
In contrast, a previous study demonstrated that rotations around the z axis resulted in better 
performance than rotations around the x- or y- axes79. A previous study examined mental rotation 
ability in subjects at risk for AD and found that there were no behavioral differences in reaction 
time or accuracy, but there were increases in activation in the right superior parietal lobule, the 
right insula, the right middle frontal gyrus, and the right inferior frontal gyrus80. In the future, the 
oddity detection task could be paired with fMRI to determine if there are any differences in 
activation in any of the brain areas associated with mental rotation. 
 
We used eyetracking to determine if there were any behavioral differences in viewing behavior 
during this task. We found that although there was a modest difference in accuracy when 
viewing Greeble stimuli, there were no differences in the within-between ratio during the 
Greeble portion of the task. This indicates that the difference in accuracy is not due to a change 
in the number of complex features that the subject is able to hold in memory at once.  
 
Because there was a difference between groups in this task, it is possible that there is some early 
pathology present in the perirhinal cortex in this group.  
 
Face/Name/Occupation Memory 
 
The FNO task was designed to target the CA1 region of the hippocampus, which is activated 
during paired association tasks67. Previous studies have indicated that face/name memory is 
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impaired in aMCI and AD patients68 and performance on a face/name memory task correlates 
with amyloid load in cognitively normal older adults81. We were surprised to see that there was 
no difference between groups in the face/name component of the task, but there was a 
statistically significant difference between groups in the face/occupation component of the task. 
This is especially surprising because both groups of subjects performed worse at face/name 
memory than face/occupation memory.  
 
The node structure theory (NST)82 posits that there are semantic and phonological nodes 
underlying lexical nodes (words or names). These nodes connect to each other, and priming is 
transmitted through these connections. In order to activate a node, it needs to be primed through 
its connections. When a node has been sufficiently primed, its contents become available. In 
order to produce a word, a thought must first activate semantic nodes, then these transmit 
priming to the lexical node, which in turn activates the phonological nodes to form the word.   
 
It is easier to remember occupational information because there are more semantic nodes 
connected to the idea of an occupation. For example, to remember that someone is a farmer you 
might remember that he or she wears overalls or wakes up early. Names are largely connected to 
phonological nodes, therefore there are fewer routes through which name information can be 
accessed. 
 
 
Previous studies have shown that both older and younger adults make more name errors than 
occupation errors but older adults make more name errors than younger adults83. Older and 
younger adults make the same number of occupation errors. In this study we found that people at 
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risk for AD make more occupation errors compared to name errors compared to controls. It is 
possible that the at risk subjects are having more difficulty accessing multiple nodes. Trouble 
accessing nodes may be a sign of inadequate priming, and a weakened connection between 
nodes.  
 
Interestingly, a recent study has shown that an area of the anterior temporal lobe, the ventral 
anterior temporal lobe face area (vATL), responds to conceptual information about an unknown 
face such as name and occupation84,85. In particular, the right vATL was sensitive to 
face/occupation information in an fMRI multivoxel pattern analysis86. The vATL is in or near the 
perirhinal cortex, the region of the brain first impacted by AD pathology. Since there was a 
difference in occupation memory but not face memory between groups, it is possible that the 
right vATL is being disproportionately affected by early AD pathology.  
 
 
 
Object/Place Memory 
 
The object/place task was also chose to test visuospatial associational memory in the CA1 region 
of the hippocampus67,87. Visuospatial associative learning is impaired in the earliest stages of AD, 
and is able to discriminate older adults who will develop AD in the future88,89We aimed to make 
this task as ecologically valid as possible by replicating the context of a common memory 
complaint, i.e. forgetting where an object was placed. We found that there was no difference 
between subject groups in any of the parameters that were examined. 
 
Previous studies indicating that visuospatial abilities decline prior to an AD diagnosis have 
shown that this decline occurs approximately three years before diagnosis90. For this study, 
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subjects were middle aged, and diagnosis would not be anticipated for a decade or more. It is 
possible that this brain region has not begun to be affected by AD pathology. In animal studies, 
widespread networks have been associated with spatial association memory including the 
hippocampus, the perirhinal cortex, and the prefrontal cortex87,91. Because of the diffuse brain 
regions involved in this task and the unlikelihood that AD pathology is present in all of the 
regions, this task may not be able to detect differences in this age group.  
 
One limitation to the ecological validity of this task is that subjects are using a two-dimensional 
screen to accomplish a task that is done in a three-dimensional world. Different neural systems 
are likely involved in processing a two-dimensional scene vs. navigating a complex three-
dimensional environment. This issue can be addressed in future studies using virtual reality 
systems92. Subjects would be able to navigate and place objects in a virtual environment, and 
then be tested for the memory of those object locations. 
 
 
Pattern Separation 
 
Pattern separation was chosen to evaluate the function of the dentate gyrus and CA3 regions of 
the brain93, These are among the last regions of the medial temporal lobe affected by AD 
pathology94, therefore we did not anticipate that at risk subjects would perform more poorly than 
control subjects.  As expected, we did not find a significant difference in subjects in pattern 
separation. 
 
Interestingly, we did find a trend toward a difference in our definition of pattern completion, i.e. 
calling a similar item “old”.  We found that at risk subjects tend to have a higher rate of pattern 
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completion than controls. There has been some debate in the literature over whether pattern 
separation and pattern completion operate completely independently, or if there is competition in 
the hippocampus for each, resulting in a functional trade-off. Some studies have shown that 
typically when rates of pattern separation go down, rates of pattern completion rise, particularly 
in older adults95, while others have shown that a decrease in pattern separation due to 
hippocampal damage does not always result in an increase in pattern separation72,96.  
 
There are two potential mechanisms by which pattern completion would occur: the first is that 
the memory for the object to be remembered has been degraded in some way, and the second is 
that the object was insufficiently encoded. Using eye-tracking, a previous study has 
demonstrated that pattern completion is likely due to insufficient encoding97. Successful 
encoding depends on a complex interaction between the prefrontal cortex and medial temporal 
lobe structures, and the connectivity of this network has been shown to be impaired in MCI98. 
Future studies in this population would benefit from using eye-tracking and/or fMRI to better 
understand the contribution of encoding processes underlying an increase in pattern completion.  
 
Overall Discussion 
This work has indicated that there are detectible cognitive differences between subjects at risk 
for AD and age-matched controls. AD pathology, and in particular tau pathology, begins in the 
perirhinal and entorhinal cortices, then enters the CA1, before finally entering the CA3 and 
dentate gyrus. Our hypothesis was that the at risk subjects would perform worse in oddity 
detection, which is dependent on intact perirhinal cortex function. If they performed worse in 
oddity detection, they would perform worse in face/name and/or object/place memory, which are 
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dependent on intact CA1 function. Finally, if they performed worse in the other tasks they may 
perform worse in pattern separation, which is dependent on intact CA3 and dentate gyrus 
function. We did not anticipate that group differences would occur in any other order.  
 
We found that subjects did perform differently in the oddity detection task and the face/name 
memory task, but not in the object/place memory task or the pattern separation task. This result 
fits with our hypothesis and indicates that AD pathology may already be present in the perirhinal 
cortex and possibly the CA1 region of the hippocampus, but not in the dentate gyrus or CA3 
region of the hippocampus. Due to previous work examining the earliest stages of AD pathology, 
we believe that these changes are likely due to underlying tau pathology and not amyloid 
pathology.  
 
Novel PET ligands have been developed that are able to detect tau pathology in vivo48. Future 
studies should use this PET scan in conjunction with the cognitive tasks developed here to better 
understand the impact tau pathology may have on these cognitive tasks.   
 
While our primary method of categorizing at risk subjects was based on family history, we also 
did secondary analyses where we examined carrier status of ApoE4, the most common risk gene 
for AD. We did not find any significant differences in any cognitive test when we analyzed data 
this way. This provides further evidence that family history of AD may be a stronger risk factor 
than ApoE4 carrier status.  
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Conclusion 
 
 We found that the at risk group performed worse than the controls in the oddity detection task 
and the FNO task, although only for select stimuli. Subjects did not differ in the object/place task 
or in the pattern separation task, although there was a trend toward a difference in bias-corrected 
pattern completion. Together, these results indicate that AD pathology may impact cognitive 
function in subtle ways in the earliest stages of the disease.   
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CHAPTER IV 
NEUROVASCULAR IMAGING METHODS DO NOT PREDICT 
RISK OF ALZHEIMER’S DISEASE IN MIDDLE AGED SUBJECTS 
Introduction 
Multiple studies have suggested that vascular physiology likely plays a role in the progression of 
AD55,99,100. Epidemiological studies have indicated that AD shares a number of risk factors with 
cardiovascular disease including hypertension15-17, hypercholesterolemia18,19, diabetes 
mellitus20,21, atherosclerosis22,23, smoking24, and obesity25. Post mortem studies have indicated that 
most AD brains exhibit vascular pathology such as microvascular disease, periventricular white 
matter lesions, and cerebral amyloid angiopathy26,27. Furthermore amyloid beta (Ab), one of the 
hallmark characteristics of AD, interferes with vascular function28,29. Despite this evidence, it is 
unclear whether vascular or amyloid pathology arises first. The two-hit theory of AD posits that 
some vascular insult (the first hit) which may be related to aging or vascular risk factors results 
in changes to the blood brain barrier and hypoperfusion. This contributes to the production, 
accumulation, and impaired clearance of Ab (second hit), which ultimately leads to the tissue 
damage and dementia associated with AD55. Lending support to this theory is the observation 
that in transgenic mice overexpressing the Swedish mutation of App cerebrovascular dysfunction 
develops earlier than cognitive changes and Ab plaque formation56,57.  
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If vascular abnormalities are present early in the pathogenesis of AD, this would have a two-fold 
significance. First, it would highlight the need to better manage vascular risk factors, and 
potentially lead to more aggressive medical treatment of cerebrovascular and cardiovascular 
disease, as is currently being investigated as part of a large-scale multi-site trial101. Secondly, in 
vivo knowledge of functional neurodegeneration is largely based on Positron Emission 
Tomography (PET) and more recently functional Magnetic Resonance Imaging (fMRI), both of 
which do not measure neuronal activity directly but rather indirectly through either metabolic 
(18F-fluorodeoxyglucose PET) or blood flow and oxygenation changes (15O PET, blood 
oxygenation level dependent [BOLD] fMRI, and arterial spin labeling [ASL] fMRI). In recent 
years BOLD fMRI has become a common method used to study brain function in living humans 
due to its inexpensive and noninvasive nature compared to PET. During neural activation there is 
a moderate increase in oxygen consumption followed by a larger increase in cerebral blood flow 
(CBF) to the activated region. BOLD fMRI takes advantage of this mismatch in CBF and oxygen 
consumption to identify areas of neural activation, usually while the subject is performing a 
specific task.  
 
Since its introduction in the early 1990s thousands of papers have been published using BOLD 
fMRI to better understand AD, and these studies have identified both increases and decreases in 
BOLD signal change compared to the normal population during various tasks102. The results of 
these studies have been particularly inconclusive in studies of healthy subjects at risk for AD103  
The reported changes in BOLD response have often been attributed to either neural dysfunction 
or compensatory mechanisms, however these changes may instead be due to regional alterations 
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in cerebrovascular function. A full understanding of vascular changes associated with AD 
throughout the lifespan is necessary for the accurate interpretation of these studies. 
 
Subjects with AD have a reported 40% lower rate of cerebral blood flow (CBF) compared to 
cognitively normal controls throughout the brain30,31, and evidence has shown that hypoperfusion 
may precede clinical symptoms32. Mounting evidence has indicated that cerebrovascular 
dysfunction may occur decades before a diagnosis. Young adults who carry the epsilon 4 variant 
of the apolipoprotein E gene (ApoE4+), a known risk gene for AD59,60, have shown increases, 
decreases, or no differences in cerebral blood flow (CBF) depending on the brain region 
studied104-106. In middle-aged subjects at risk for AD based on ApoE status and/or family history, 
the results have also been mixed with both hypoperfusion107 and hyperperfusion108 being 
observed. Wierenga et. al. have posited that there may be a biphasic curve of CBF function in 
AD with increased CBF early in life, followed by reduced CBF as the disease advances33. It is 
currently unclear whether these early changes in CBF are due to vascular factors, neural factors, 
or some combination of the two. In order to address this, it would be valuable to measure a factor 
that is strictly vascular (i.e. not neuronal), in conjunction with a behavioral task that relies on 
intact neuronal function without depending on vascular factors as a surrogate for neural activity. 
If subjects in the earliest stages of AD have compromised vascular function, but there is no 
evidence of a behavioral impairment, that indicates that perhaps vascular damage precedes 
neuronal damage. Conversely, if subjects in the earliest stages of AD demonstrate behavioral 
changes but no differences in vasculature, that indicates that neuronal damage precedes vascular 
damage.   
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Cerebrovascular reactivity, i.e. the responsiveness of cerebral blood vessels, can be quantified in 
the brain by comparing rates of blood flow at rest to blood flow during a vasoactive stimulus. 
Typically, the vasoactive stimulus is hypercapnia induced by breath holding, the inhalation of a 
low concentration of carbon dioxide, or administration of acetazolamide. The value of a 
hypercapnic stimulus is that it operates by activating endothelial nitric oxide synthase in vascular 
endothelial cells, and thus it bypasses any neural influences. The majority of previous research 
has shown that CVR is impaired in subjects diagnosed with AD34-42. Two studies have failed to 
find a difference in AD patients compared to controls109,110, however both of these studies 
quantified CVR using Positron Emission Tomography (PET) imaging. Studies examining CVR 
in subjects with Mild Cognitive Impairment (MCI), a prodromal form of AD, have also 
demonstrated a reduction in CVR in patients compared to controls38,39. 
 
If cerebrovascular dysfunction is present early in the AD disease process, it is possible that CVR 
is impaired many years before a diagnosis. Interestingly, a recent study has shown that young 
ApoE4+ subjects have reduced cerebrovascular reactivity compared to carriers of the 
neuroprotective ApoE2 allele111. To our knowledge, no study has been done comparing CVR in 
middle aged adults at risk for AD to age-matched controls.  
 
In the present study, CBF and CVR are examined in cognitively healthy middle-aged (40-60 yrs) 
subjects at increased risk for AD. Although we collected data on carrier status for Apolipoprotein 
E, the most common risk gene for AD, we based our risk status on first degree family history as 
there is evidence that family history is a stronger predictor of disease58,112. We focused our a 
priori region of interest (ROI) analyses specifically on the area of the brain primarily affected by 
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AD, i.e. the hippocampus, and total gray matter. ROI analyses were done in native space to avoid 
any registration deficits as a result of aging and/or AD-related tissue atrophy. We also used a 
discovery-driven approach to identify any other regions that were different between at risk and 
control subjects. We hypothesized that subjects at risk for AD would demonstrate increased CBF 
and decreased CVR compared to control subjects, but no differences in brain volume. 
 
Methods 
Subjects 
Methods for recruitment and screening, demographic data collection, neuropsychological data 
collection, and genetic data collection are described in Chapter II. 
 
Scanning Session 
All scans were completed using a scanner with a field strength of 3.0T (Philips Medical Systems, 
Best, The Netherlands) using a 32-channel receive array head coil and a body coil for 
radiofrequency transmission. The entire MRI protocol took approximately 45 minutes. The 
subject wore an oxygen mask, nasal cannula, and pulse oximeter for the duration of the scanning 
session. For all scans except those used for cerebrovascular reactivity (CVR) calculation, the 
subject inhaled medical air (21% O2/79% N2). Subjects were continually monitored for heart rate, 
pulse oxygenation level, and end-tidal CO2 (EtCO2). 
 
Image Acquisition 
i. Structural Imaging 
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For image registration and volumetric analyses, a T1-weighted image was acquired (MPRAGE, 
TE=3.7, TR=8 ms, spatial resolution=1x1x1 mm3). 
 
ii. Perfusion imaging 
A gradient-echo single-shot echo planar imaging (factor=37) pseudo-continuous arterial spin 
labeling (pCASL) sequence was used with total labeling duration=1650 ms. TR/TE = 4000/13 
ms; spatial resolution = 3x3x7 mm3; slices=17. Background suppression was used concomitantly 
to suppress signal from gray and white matter static tissue. A total of 30 tag/control pairs were 
collected for each pCASL scan. An equilibrium magnetization image (M0) was acquired with 
identical spatial resolution and readout as the pCASL scan, but with repetition time=20 seconds 
and all background suppression and labeling pulses removed.  
 
iii. Hypercapnia Challenge 
To quantify CVR, subjects inhaled a hypercapnic gas mixture (5% CO2/21% O2/74% N2) for 
approximately 4 minutes. The sequences and parameters used for the baseline and hypercapnic 
scans were identical. 
 
Image Analysis 
 
i. Cerebral blood flow 
For pCASL scans acquired at baseline and during the hypercapnia challenge, the difference 
between control and label images was pair-wise subtracted after which the mean difference 
image was calculated. CBF values were then quantified using the optimized method described by 
Alsop et al113: 
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𝐶𝐵𝐹 = 6000	×	𝜆	×∆𝑀	×	𝑒 -./01,345562	×	𝛼	×	𝑇:,;<==>	×	𝑀?	×	(1 − 𝑒 CD01,34556)	 
 
Where λ is the blood/brain partition coefficient and is equal to 0.9 mL/g114, ΔM is the difference 
in signal intensities in the control and label images, PLD is the post-labeling delay and is equal to 
1525 ms, T1, blood is the longitudinal relaxation time of blood at 3.0T and is equal to 1650 ms115, α 
is the labeling efficiency and is equal to 0.85116, M0 is the signal intensity of the equilibrium 
magnetization image, and τ is the label duration and is equal to 1650 ms. The units of CBF are 
mL blood/100g tissue/minute. 
 
CBF maps were linearly registered to T1 images using FSL FLIRT117,118, CBF is significantly 
reduced in white matter compared to gray matter, however due to the limited spatial resolution of 
ASL (3x3x7 mm3) many voxels contain both tissue types119. To reduce partial volume effects, 
each subject’s ASL data was co-registered to their T1-weighted structural image and the 
fractional tissue volume was calculated in each voxel using FMRIB’s Automated Segmentation 
Tool (FAST)120. Only voxels containing >85% gray matter were included in total gray matter 
analysis. All ROI calculations were performed in native space. Left and right hippocampal masks 
were created for each subject using FSL FIRST121. For the discovery-based approach, subjects’ 
CBF map was registered to the Montreal Neurological Institute 2 mm standard brain and entered 
into Randomise, FSL’s tool for nonparametric permutation inference, and analyzed with 
threshold-free cluster enhancement (TFCE)122. Data were analyzed using 500 permutations.  
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ii. Cerebrovascular reactivity 
CVR was defined as the difference in CBF between the scans with and without hypercapnia 
normalized by baseline signal (FGHIJKCFGHJLMFGHJLM ). To correct for respiration differences, that value 
was divided by the change in EtCO2 during hypercapnia (~5-10 mmHg). CVR maps were 
analyzed by region of interest and permutation analysis as described in the previous section. 
 
iii. Volume and Cortical Thickness 
The volume of the perirhinal cortex (PRC), the entorhinal cortex (ERC), and the hippocampus, 
and the cortical thickness of the PRC and ERC were calculated using FreeSurfer (version 5.3.0). 
FreeSurfer methods for segmentation of brain volumes have been previously described123-135. 
ROIs were chosen based on regions that are known to show the earliest AD pathology. All ROIs 
were defined using atlases implemented in FreeSurfer. Left and right hippocampal volumes were 
defined using the automated segmentation routine, left and right entorhinal volumes and cortical 
thickness were parcellated using the Desikan-Killiany Atlas136, and left and right perirhinal 
cortex volumes and cortical thickness were parcellated using the ex-vivo Broadmann Area 
Atlas137.Volumes were normalized by total brain volume.  
Results 
Subjects 
A total of 32 subjects with a family history of AD (“At Risk”) and 22 subjects with no family 
history of AD (“control”) completed the study. Subjects were matched on age, sex, race, 
diabetes, smoking history (lifetime and recent), exercise, resting heart rate, and body mass index 
(Table 4). The at risk group had significantly more carriers of the e4 variant of Apolipoprotein E 
(p=0.001, Table 4). At the time of testing, all subjects were cognitively normal, i.e., they did not 
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score >1.5 S.D. below the expected scores for his or her age on any neuropsychological test. 
There was a significant difference between groups in the immediate memory portion of the Rey-
Osterrieth Complex Figure Test, but there were no significant group differences in any other 
neuropsychological test (Table 5). 
Cerebral Blood Flow 
Blood flow maps were visually inspected before and after image registration to confirm image 
quality (Figure 11). No differences between groups were observed in the gray matter (F3,51=2.59, 
p=0.06), left hippocampus (F3,51=1.53, p=0.21), or right hippocampus (F3,51=0.95, p=0.42) after 
correcting for age, and sex (Figure 12), although there was a trend for a difference in gray matter. 
If groups were divided based on carrier status for ApoE4 rather than family history, there were 
again no differences between groups observed in the gray matter (F3,50=2.46, p=0.07), left 
hippocampus (F3,50=1.40, p=0.26), or right hippocampus (F3,50=0.81, p=0.49). The permutation 
test using TFCE did not identify any significant clusters. 
 
Cerebrovascular Reactivity 
After correcting for age and sex there were no CVR differences observed between groups in gray 
matter (F3,42=0.78, p=0.51), the left hippocampus (F3,44=1.5, p=0.24), or the right hippocampus 
(F3,47=0.54, p=0.66) (Figure 13). After dividing groups based on carrier status of ApoE4, we 
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 At Risk (n=32) Control (n=22) p-value 
Age (yrs ± s.d.) 53±6 53±6 0.94 
Sex (% female) 81 60 0.07 
Race (% non-white) 6 18 0.16 
ApoE4 (% carriers) 63 18 0.001** 
Diabetes (%) 3 0 0.419 
Smoking in the past month (%) 9 9 1 
Lifetime smoking (%) 27 27 1 
Exercise (rating out of 4 ± s.d.) 3.5±0.9 3.2±1 0.24 
Resting heart rate (beats per minute ± s.d.) 70±12 71±11 0.861 
Body mass index (mean ± s.d.) 28±5 27±6 0.453 
 
 
 
  
Table 4: Demographic data. There were no significant differences 
between groups in age, sex, or race. There were also no differences 
between groups in history of diabetes, smoking, exercise, resting 
heart rate, or body mass index. There were significantly more ApoE4 
carriers in the at risk group (p=0.001). 
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 At Risk (n=32) 
Mean (SEM) 
Control (n=22) 
Mean (SEM) 
p-value 
MMSE 29.89 (0.06) 29.8 (0.1) 0.36 
LM-I 28 (1) 28 (1) 0.85 
LM-D 24 (1) 24 (1) 0.92 
LM-R 26.1 (0.4) 26.4 (0.4) 0.61 
REYO-C 34.8 (0.3) 35.2 (0.3) 0.32 
REYO-I 21 (1) 23.6 (0.9) 0.045* 
REYO-D 21 (1) 23.3 (0.9) 0.09 
FAS 42 (2) 48 (3) 0.10 
CAT 57 (2) 61 (2) 0.23 
Trails A 26 (1) 28 (1) 0.21 
Trails B 56 (2) 60 (2) 0.23 
CERAD-I 24.1 (0.5) 25 (0.6) 0.24 
CERAD-D 7.8 (0.3) 8.5 (0.3) 0.11 
CERAD-R 9.85 (0.08) 9.91 (0.06) 0.58 
JLO 23.6 (0.7) 25.4 (0.9) 0.14 
BNT 57.1 (0.6) 57.4 (0.7) 0.72 
Tower 493 (32) 476 (35) 0.72 
 
Table 5: Neuropsychological testing. There were a significant difference between groups in the 
immediate memory portion of the Rey-Osterrieth Complex Figure Test. No other significant 
differences were found. MMSE = Mini Mental State Exam, LM-I = Delis Kaplan Executive 
Function System (DKEFS) Logical Memory Test Immediate Recall, LM-D = DKEFS Logical 
Memory Test Delayed Recall, LM-R – DKEFS Logical Memory Test Recognition, REYO-C = 
Rey Osterrieth Complex Figure Test (REYO) Copy, REYO-I = REYO Immediate Recall, 
REYO-D = REYO Delayed Recall, FAS = DKEFS Verbal Fluency, CAT = DKEFS Semantic 
Fluency, CERAD-I= Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) 
Word List Learning- Immediate Recall, CERAD-D = CERAD Word List Learning Delayed 
Recall, CERAD-R = CERAD Word List Learning Recognition, J-LO = Benton Judgment of 
Line Orientation, BNT = Boston Naming Test, Tower = DKEFS Tower Test  
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again found no differences between groups in gray matter (F3,39=1.20, p=0.33), the left 
hippocampus (F3,39=0.78, p=0.51), or the right hippocampus (F3,39=1.05, p=0.38) The permutation 
test using TFCE did not identify any significant clusters. 
 
Volume and Cortical Thickness 
 
After segmenting the brain into pre-defined regions of interest (left and right PRC, ERC, and 
hippocampus), volumes were calculated and normalized by total brain volume. The cortical 
thickness of each cortical region (the PRC and ERC) were also calculated. After correcting for 
age and sex no differences were found between groups in any region studied (Figure 14). There 
were also no cortical thickness or volume differences observed in any brain region when groups 
were divided based on carrier status of ApoE4 (Figure 15). 
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Figure 11: Representative images of neurovascular imaging. All CBF and CVR maps were 
visually inspected and registered to the subjects’ T1 image. 
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Figure 12: Cerebral blood flow results. No statistically significant differences were found in 
CBF between the at risk group and the control group in any region studied. Error bars are 
SEM 
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Figure 13: Cerebrovascular reactivity results. No statistically significant differences were 
found in CVR between the at risk group and the control group in any region studied. Error 
bars are SEM. 
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Figure 14: Volumetric results by family history. There were no between group 
differences in A. cortical thickness, B. Normalized gray matter volume, or C. Region of 
interest volumes in any region studied.  
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Figure 15: Volumetric results by ApoE4 Carrier Status. There were no between group 
differences in A. cortical thickness, B. Normalized gray matter volume, or C. Region of 
interest volumes in any region studied.  
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C 
	65	
Discussion 
The aim of this study was to determine if middle aged subjects who are at increased risk for 
developing AD in the future show any functional cerebrovascular differences. To determine this, 
arterial spin labeling in conjunction with a hypercapnic challenge was used to measure cerebral 
blood flow and cerebrovascular reactivity. We found that there were no significant differences 
between groups in either cerebral blood flow, or cerebrovascular reactivity. 
 
Measuring cerebral blood flow has been described as a potentially useful method for identifying 
candidates for future AD trials who are currently in the preclinical phase of the disease138. 
Previous studies have indicated that subjects at risk for AD have higher resting CBF than 
controls33,104,108, however we did not observe any differences between groups whether 
determining risk based on family history or ApoE4 carrier status. Wierenga et. al. have posited 
that CBF may be higher in subjects at risk for AD, but while AD advances CBF becomes lower 
than controls139. Weirenga’s theory is based on work that has been done in younger adults (20s)33 
at risk due to ApoE4 carrier status, older adults (60s+)140 at risk due to ApoE4 carrier status, and 
MCI and AD patients.  One other study investigated CBF in middle aged adults (age 40-65 
years) and found evidence of hypoperfusion in the right superior and middle frontal cortices of 
subjects with a family history of AD compared to controls. They did not find any significant 
differences between groups in the medial temporal lobes. Subjects in their 40s and 50s are at an 
age in which we expect that some AD pathology is present, but it isn’t yet debilitating. It is 
possible that the 40s and 50s are the transition point between hyper- and hypoperfusion, which 
would make it difficult to detect any differences between groups. There may be real changes 
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taking place in the cerebrovasculature, but methods such as ASL are not sufficiently sensitive to 
identify these changes. 
 
Another study that looked at hypoperfusion in healthy middle aged adults with and without a 
family history of AD found that there was only minimal hypoperfusion in the group with a 
family history, but when only the subjects with a maternal history of AD were analyzed there 
was a significant difference between groups107. We did not collect information on maternal vs. 
paternal history of AD in this group, but it is possible that if we had broken the data down in this 
way we would have found a significant result. If that is true, that raises the question of why 
maternal history in particular would be driving perfusion differences between groups, and is 
worth further study. 
 
Cerebrovascular reactivity is an index by which the dilatory capacity of blood vessels can be 
measured. A deficit in CVR would indicate that blood vessels have difficulty expanding in 
response to a vasoactive stimulus such as hypercapnia. Previous studies have shown that CVR is 
diminished in animal models of AD, and AD patients37,141,142. In studies of cerebrovascular aging, 
CVR seems to decline earlier and at a greater rate than CBF143, so we predicted that subjects at 
risk for AD would have decreased CVR compared to controls even if there were no detectible 
differences in CBF. We found that there were no differences between groups in any region in our 
measure of CVR when groups were divided based on either family history or ApoE4 carrier 
status. Arterial spin labeling has been shown to be a reliable method for the quantification of 
CVR and comparable with techniques that have used BOLD measures, particularly in the frontal 
and temporal lobes144. The average CVR maps that were generated individually and for each 
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group demonstrate a low signal to noise ratio, so it is possible that there is a difference in CVR 
between groups, but it is not detectible. Detection could be improved by further optimizing the 
pCASL sequence, or adjusting the background suppression pulses. BOLD imaging has a higher 
signal to noise ratio than pCASL, so repeating the experiment using BOLD may provide 
additional information.  
 
If there truly are no differences between the at risk group and the control group in 
cerebrovascular function, this would lend additional support to neuroimaging studies that have 
used BOLD fMRI to assess neural activation and/or connectivity. BOLD fMRI relies on intact 
vascular function. There are thousands of published studies that have used BOLD fMRI as a 
marker of neural dysfunction, but changes in vasculature would limit the interpretability of those 
studies. The current study has not demonstrated any differences in vascular function between 
groups, meaning that fMRI studies in this population may not need to adjust for vascular 
insufficiencies and can be interpreted as neural changes.  
 
As expected, no differences were observed in tissue volume or cortical thickness in any region 
that was studied when determining risk based on either family history or ApoE4 carrier status. 
Subjects are relatively young (40-50 years old) and we would not anticipate that they would be 
experiencing any AD-related tissue atrophy at this stage. 
 
One of the major limitations to this study is that it is cross-sectional rather than longitudinal. We 
currently have no way of knowing if the at risk group will go on to develop AD in the future. If 
	68	
we were able to revisit these subjects in 10-20 years to assess who developed AD and who 
didn’t, it would give us a better idea of the changes that are taking place in preclinical AD. 
 
Conclusions 
Based on previous studies, we hypothesized that subjects would have increased cerebral blood 
flow and deceased cerebrovascular reactivity. We found that there were no significant 
differences between groups in either CBF or CVR. There were also no significant differences 
between groups in the volume or cortical thickness of any region studied.  
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CHAPTER V 
CEREBROVASCULAR REACTIVITY, BUT NOT CEREBRAL 
BLOOD FLOW, CORRELATES WITH COGNITION IN SUBJECTS 
AT RISK FOR ALZHEIMER’S DISEASE 
Introduction 
 
In the earliest stages of AD, there are likely complex interactions occurring between different 
physiological processes. In order to better understand these interactions, it is useful to determine 
if any potential early biomarkers of the disease correlate with one other.   The first aim of this 
study was to determine if four cognitive tests that relied on various structures of the medial 
temporal lobe (oddity detection, face/name/occupation memory, object/place memory, and 
pattern separation) were impaired in subjects at risk for AD. The second aim of this study was to 
determine if imaging markers of neurovascular function (cerebral blood flow and 
cerebrovascular reactivity) were either higher or lower in subjects at risk for AD, indicating early 
neurovascular impairments. Neurovascular function has been shown to correlate with cognitive 
function35,37,40,145-147, therefore the third aim of this study was to determine if neurovascular 
function was correlated with cognitive function in these subjects using the specific cognitive 
tests and neuroimaging methodology described previously. We wanted to determine if the 
relationship between these factors differs in subjects at risk for AD compared to control subjects.  
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Identifying correlations between neuroimaging and cognition has been difficult in the past due to 
an inherent circularity in the analyses148 or not controlling for underlying factors such as age or 
education149. Because our neuroimaging markers were vascular in nature and didn’t involve any 
psychological manipulation, we did not feel that circular analyses would be an issue. In addition, 
we corrected for age in all of our correlations. Pearson correlations can be sensitive to outliers, so 
we carefully removed outliers from analyses. 
 
We hypothesized that a higher rate of cerebral blood flow (CBF) and a lower rate of 
cerebrovascular reactivity (CVR) would be correlated with reduced performance in the cognitive 
tasks. As we presented in Chapter III, the cognitive tasks were designed to target the areas that 
are first impacted by AD pathology49, therefore we anticipated that oddity detection (perirhinal 
cortex) would correlate most strongly with neurovascular function, followed by 
face/name/occupation memory (CA1), object/place memory (CA1), and pattern separation 
(DG/CA3).  
 
Methods 
Subjects 
Methods for recruitment and screening, demographic data collection, neuropsychological data 
collection, and genetic data collection are described in Chapter II.  
Cognitive Tests 
All cognitive tests used in this analysis were described in Chapter III. To reduce the number of 
comparisons, only the variables that we considered most relevant for each cognitive test were 
included in correlational analyses. For the oddity detection task, accuracy and the within between 
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ratio in the four stimuli categories were included. For the face/name/occupation task, accuracy in 
face/name memory, accuracy in face/occupation memory, and total accuracy were included. For 
the object/place task accuracy, distance from target, and incorrect distance from the target were 
included. For pattern separation, accuracy, responding “old” to a lure stimulus (uncorrected 
pattern completion), responding “similar” to a lure stimulus (uncorrected pattern separation), 
bias-corrected pattern separation, and bias-corrected pattern completion were included.   
Neurovascular Tests 
Neurovascular tests were done as described in Chapter IV. Again, only the most relevant 
variables were included in correlational analyses. For both CBF and CVR, only the right and left 
hippocampi and total gray matter were included. If a correlation was found between a behavioral 
measure and total gray matter, a further analysis was done to determine if a particular brain lobe 
was driving the correlation. The CBF and CVR maps were registered to the Montreal 
Neurological Institute’s 2 mm brain atlas using FSL FLIRT117,118, and the brain was segmented 
into the four major brain lobes (frontal, occipital, parietal, and temporal) using a probabilistic 
atlas thresholded at 50%. 
Statistical Tests 
Data were inspected for outliers, and any outliers were removed from analyses. Outliers were 
defined as >1.5 times the interquartile range (IQR). A zero-order Pearson’s correlation analysis 
was done correcting for age. Missing values were handled pairwise.  
 
Because of the relatively small number of subjects we had compared to many clinical correlation 
studies, and the high number of comparisons we made, we felt that correcting for multiple 
comparisons may result in a high number of type II errors (false negatives). It has been suggested 
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that often in clinical research it may be more appropriate to report the statistical tests used and 
keep the multiple comparison problem in mind while interpreting the results, rather than 
performing a multiple comparison correction outright150. We chose to report results without 
performing this correction. 
 
 
Results 
At Risk Subjects 
 
i. Oddity Detection and Neurovasculature 
 
A significant positive correlation was found between the within/between ratio when viewing face 
stimuli, and CVR in total gray matter (rs=0.46, p=0.03), which indicates that subjects with higher 
CVR performed better in this task. To better understand if a specific brain lobe was driving this 
correlation, gray matter was further segmented into the major brain lobes (frontal, occipital, 
parietal, and temporal) and it was found that there were no significant correlations between face 
within/between ratio and any specific brain lobe, although there was a trend toward a negative 
correlation between face within/between ratio and the occipital lobe (rs=-0.392, p=0.058) and a 
positive correlation between face within/between ratio and the parietal lobe (rs=0.381, p=0.067) 
A higher within/between ratio is indicative of a higher binding ability of complex features, so 
increased CVR in the parietal lobe may improve binding ability.  
 
ii. Face/Name/Occupation Memory and Neurovasculature 
 
A significant negative correlation was found between cerebrovascular reactivity in the left 
hippocampus and face/name memory accuracy (rs=-0.45, p=0.03), which indicates that subjects 
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with higher CVR in the hippocampus perform worse on this task. No other significant 
relationships were found.  
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   Accuracy Within-Between Ratio 
   Face Object Scene Greeble Face Object Scene Greeble 
Cerebral Blood 
Flow 
Left 
Hippocampus 
rs 0.17 0.04 -0.01 -0.07 -0.24 -0.17 -0.08 -0.31 
p 0.38 0.86 0.98 0.74 0.20 0.37 0.69 0.09 
d.f. 27 28 28 27 28 27 28 28 
Right 
Hippocampus 
rs 0.07 0.05 -0.01 0.04 -0.15 -0.14 -0.01 -0.24 
p 0.72 0.80 0.95 0.84 0.43 0.47 0.97 0.21 
d.f. 27 28 28 27 28 27 28 28 
Gray Matter rs 0.08 0.21 0.10 0.20 0.09 0.12 0.09 -0.26 
p 0.69 0.28 0.61 0.30 0.66 0.56 0.65 0.18 
d.f. 26 27 27 26 27 26 27 27 
Cerebrovascular 
Reactivity 
Left 
Hippocampus 
rs -0.04 0.08 -0.03 -0.21 -0.09 0.19 -0.23 -0.05 
p 0.87 0.71 0.90 0.34 0.66 0.39 0.27 0.80 
d.f. 22 23 23 22 23 22 23 23 
Right 
Hippocampus 
rs -0.32 0.02 0.09 0.03 0.00 0.06 -0.10 -0.06 
p 0.10 0.94 0.65 0.90 0.99 0.76 0.60 0.76 
d.f. 25 26 26 25 26 25 26 26 
Gray Matter rs -0.10 0.01 0.11 0.30 0.46 0.34 0.20 0.18 
p 0.67 0.96 0.60 0.17 0.03* 0.11 0.36 0.40 
d.f. 21 22 22 21 22 21 22 22 
 
 
Brain Region Face Within-Between Ratio 
Cerebrovascular Reactivity 
Frontal Lobe r 0.211 
 p 0.323   d.f. 22 
Occipital Lobe r -0.392 
 p 0.058   d.f. 22 
Parietal Lobe r 0.381 
 p 0.067   d.f. 22 
Temporal Lobe r 0.248 
 p 0.244   d.f. 22 
 
 
Table 6: Correlations between CBF and CVR and behavioral measures from the oddity detection 
task in at risk subjects. A significant correlation was found between the within-between ratio 
when viewing face stimuli and gray matter CVR. 
Table 7: Correlations CVR and Face Within-Between Ratios broken down by brain lobe. There 
were no significant correlations between CVR in any specific lobe and Face Within-Between 
Ratio, although there is a trend toward a correlation in the occipital lobe and parietal lobe.  
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   Total Accuracy Name Accuracy Occupation Accuracy 
Cerebral Blood Flow Left 
Hippocampus 
rs -0.06 -0.04 -0.13 
p 0.76 0.85 0.50 
d.f. 28 28 29 
Right 
Hippocampus 
rs 0.02 0.00 -0.03 
p 0.91 0.99 0.87 
d.f. 28 28 29 
Gray Matter rs -0.17 -0.25 -0.04 
p 0.37 0.19 0.83 
d.f. 27 27 28 
Cerebrovascular 
Reactivity 
Left 
Hippocampus 
rs -0.36 -0.45 0.02 
p 0.08 0.03* 0.91 
d.f. 22 22 23 
Right 
Hippocampus 
rs 0.00 -0.13 0.28 
p 0.99 0.51 0.14 
d.f. 25 25 26 
Gray Matter rs -0.16 -0.24 0.14 
p 0.47 0.28 0.51 
d.f. 21 21 22 
 
  
Table 8: Correlations between CBF and CVR and behavioral measures from the 
face/name/occupation memory task in at risk subjects. A significant correlation was found 
between face/name memory and CVR in the left hippocampus. 
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iii. Object/Place Memory and Neurovasculature 
 
Several significant correlations were found between CVR and object/place memory. There was a 
negative correlation found between distance from target and right hippocampus CVR (rs=-0.38, 
p=0.046) and distance from target and gray matter CVR (rs=-0.46, p=0.02). There was also a 
positive correlation found between accuracy and right hippocampus CVR (rs=0.4, p=0.04) and 
accuracy and gray matter CVR (rs=0.51, p=0.01). These results indicate that, in general, higher 
CVR in the right hippocampus and gray matter results in a better performance on this task. To 
better understand if any specific brain lobe was driving the trend in gray matter, the brain was 
further segmented into the major brain lobes (frontal, occipital, parietal, and temporal) and it was 
found that there were no significant correlations between distance from target and any brain lobe. 
There were also no significant correlations found between accuracy and any brain lobe, although 
there was a trend toward a positive correlation between accuracy and CVR in the parietal lobe 
(rs=0.403, p=0.051).  
 
iv. Pattern Separation and Neurovasculature 
 
No significant correlations were found between performance in the pattern separation task and 
any neurosvascular factor studied. 
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   Distance Accuracy Incorrect Distance 
Cerebral Blood Flow Left Hippocampus rs 0.17 -0.18 0.05 
p 0.36 0.35 0.79 
d.f. 28 28 25 
Right Hippocampus rs 0.11 -0.12 0.13 
p 0.55 0.55 0.52 
d.f. 28 28 25 
Gray Matter rs -0.13 0.17 0.30 
p 0.51 0.38 0.13 
d.f. 27 27 24 
Cerebrovascular Reactivity Left Hippocampus rs 0.32 -0.24 0.23 
p 0.12 0.24 0.32 
d.f. 23 23 20 
Right Hippocampus rs -0.38 0.40 0.12 
p 0.046* 0.04* 0.56 
d.f. 26 26 23 
Gray Matter rs -0.46 0.51 0.29 
p 0.02* 0.01* 0.20 
d.f. 22 22 19 
  
Brain Region Distance Accuracy 
Cerebrovascular Reactivity 
Frontal Lobe r -0.337 0.381 
 p 0.107 0.66   d.f. 22 22 
Occipital Lobe r -0.299 0.318 
 p 0.155 0.13   d.f. 22 22 
Parietal Lobe r -0.310 0.403 
 p 0.141 0.051   d.f. 22 22 
Temporal Lobe r -0.173 0.292 
 p 0.418 0.166   d.f. 22 22 
 
 
 
 
Table 9: Correlations between CBF and CVR and behavioral measures from the object/place 
memory task in at risk subjects. Significant correlations were found between distance and 
accuracy in the task and right hippocampus and gray matter CVR.  
Table 10: Correlations CVR and Object Place measures broken down by brain lobe. There were 
no significant correlations between CVR in any specific lobe and Object Place measures, 
although there is a trend toward a correlation between accuracy and CVR in the parietal lobe.  
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   Responses to Lures Accuracy Pattern 
Separation 
Pattern 
Completion    “Old” “Similar” 
Cerebral Blood 
Flow 
Left 
hippocampus 
rs -0.20 0.17 0.06 0.10 -0.20 
p 0.28 0.38 0.75 0.59 0.28 
d.f. 29 29 29 29 29 
Right 
Hippocampus 
rs -0.32 0.28 0.08 0.21 -0.32 
p 0.08 0.12 0.68 0.26 0.08 
d.f. 29 29 29 29 29 
Gray Matter rs -0.22 0.21 0.25 0.15 -0.26 
p 0.25 0.28 0.19 0.44 0.17 
d.f. 28 28 28 28 28 
Cerebrovascular 
Reactivity 
Left 
Hippocampus 
rs 0.12 -0.14 0.15 -0.22 0.17 
p 0.56 0.50 0.47 0.30 0.42 
d.f. 23 23 23 23 23 
Right 
Hippocampus 
rs 0.07 0.03 0.21 0.02 0.12 
p 0.71 0.90 0.28 0.91 0.55 
d.f. 26 26 26 26 26 
Gray Matter rs 0.02 0.08 0.07 0.06 0.00 
p 0.92 0.71 0.76 0.80 1.00 
d.f. 22 22 22 22 22 
 
  
Table 11: Correlations between CBF and CVR and behavioral measures from the pattern 
separation task in at risk subjects. No significant correlations were found. 
	79	
 
Control Subjects 
 
i. Oddity Detection and Neurovasculature 
 
A significant positive correlation was found between accuracy when viewing face stimuli and 
gray matter CBF (rs=0.63, p=0.01), indicating that higher CBF is associated with a better 
performance. To determine if one particular brain lobe was driving this trend, the brain was 
further segmented into the major brain lobes (frontal, occipital, parietal, and temporal). A 
significant positive correlation was found between face accuracy and CBF in the occipital lobe 
(rs=0.64, p=0.019) and the temporal lobe (rs=0.606, p=0.028) and a trend toward a positive 
correlation between face accuracy and CBF in the parietal lobe (rs=0.524, p=0.066). 
 
ii. Face/Name/Occupation Memory and Neurovasculature 
 
No significant correlations were found between face/name/occupation memory and 
neurovascular function. 
 
iii. Object/Place Memory and Neurovasculature 
 
A significant negative correlation was found between gray matter CBF and distance from target 
(rs=-0.53, p=0.02). There was also a trend toward a significant positive correlation between gray 
matter CBF and accuracy (rs=0.45, p=0.06). Both of these results indicate that higher CBF in the 
gray matter results in a better performance on this task. To determine if one particular brain lobe 
was driving this trend, the brain was further segmented into the major brain lobes (frontal, 
occipital, parietal, and temporal). A strong negative correlation was found between the parietal 
lobe and distance from target (rs=-0.689, p=0.009), and a negative correlation as found between 
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the frontal lobe and distance from target (rs=-0.575, p=0.04). There was also a trend toward a 
negative correlation between the occipital lobe and distance from target (rs=-0.521, p=0.068).  
 
iv. Pattern Separation and Neurovasculature 
 
No significant correlations were found between performance on the pattern separation task and 
neurovascular function. 
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   Accuracy Within-Between Ratio 
   Face Object Scene Greeble Face Object Scene Greeble 
Cerebral Blood 
Flow 
Left 
Hippocampus 
rs 0.29 0.14 0.08 0.31 0.11 0.24 0.14 0.21 
p 0.26 0.56 0.73 0.19 0.65 0.33 0.56 0.39 
d.f. 15 17 17 17 17 17 17 17 
Right 
Hippocampus 
rs 0.30 0.11 -0.08 0.18 0.20 0.29 0.05 0.18 
p 0.24 0.66 0.76 0.47 0.42 0.23 0.83 0.45 
d.f. 15 17 17 17 17 17 17 17 
Gray Matter rs 0.63 0.33 0.20 0.23 0.14 0.17 0.02 0.06 
p 0.01* 0.16 0.41 0.35 0.57 0.48 0.93 0.81 
d.f. 15 17 17 17 17 17 17 17 
Cerebrovascular 
Reactivity 
Left 
Hippocampus 
rs 0.15 -0.03 0.19 0.13 -0.09 0.17 -0.17 -0.19 
p 0.56 0.91 0.46 0.61 0.73 0.51 0.51 0.44 
d.f. 15 16 16 16 16 16 16 16 
Right 
Hippocampus 
rs 0.13 0.14 0.35 0.19 -0.03 0.20 0.10 0.07 
p 0.62 0.58 0.15 0.43 0.91 0.42 0.69 0.77 
d.f. 15 17 17 17 17 17 17 17 
Gray Matter rs 0.03 0.17 0.41 0.24 0.28 0.27 0.39 0.29 
p 0.90 0.51 0.09 0.34 0.25 0.28 0.12 0.24 
d.f. 15 16 16 16 16 16 16 16 
 
 
Brain Region Face Accuracy 
Cerebral Blood Flow 
Frontal Lobe r 0.446 
 p 0.127   d.f. 11 
Occipital Lobe r 0.64 
 p 0.019   d.f. 11 
Parietal Lobe r 0.524 
 p 0.066   d.f. 11 
Temporal Lobe r 0.606 
 p 0.028   d.f. 11 
 
Table 12: Correlations between CBF and CVR and behavioral measures from the oddity detection 
task in control subjects. A significant correlation was found between accuracy when viewing face 
stimuli and cerebral blood flow in gray matter. 
Table 13: Correlations between CBF and accuracy when viewing face stimuli broken down by 
brain lobe.  Significant correlations were found between CBF in the occipital lobe and the 
temporal lobe and accuracy when viewing face stimuli.  
	82	
 
 
 
   Total Accuracy Name Accuracy Occupation Accuracy 
Cerebral Blood Flow Left 
Hippocampus 
rs 0.04 -0.11 0.31 
p 0.88 0.66 0.19 
d.f. 17 17 18 
Right 
Hippocampus 
rs 0.00 -0.14 0.25 
p 0.99 0.58 0.29 
d.f. 17 17 18 
Gray Matter rs 0.30 0.19 0.20 
p 0.22 0.43 0.42 
d.f. 17 17 17 
Cerebrovascular 
Reactivity 
Left 
Hippocampus 
rs -0.11 -0.20 0.14 
p 0.66 0.43 0.58 
d.f. 16 16 16 
Right 
Hippocampus 
rs -0.31 -0.37 0.12 
p 0.20 0.12 0.62 
d.f. 17 17 17 
Gray Matter rs -0.25 -0.33 0.21 
p 0.32 0.19 0.40 
d.f. 16 16 16 
 
  
Table 14: Correlations between CBF and CVR and behavioral measures from the 
face/name/occupation memory task. No significant correlations were found.  
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   Distance Accuracy Incorrect Distance 
Cerebral Blood 
Flow 
Left Hippocampus rs -0.37 0.36 0.24 
p 0.13 0.14 0.39 
d.f. 16 16 13 
Right Hippocampus rs -0.29 0.26 0.35 
p 0.24 0.30 0.20 
d.f. 16 16 13 
Gray Matter rs -0.53 0.45 -0.09 
p 0.02* 0.06 0.75 
d.f. 16 16 13 
Cerebrovascular 
Reactivity 
Left Hippocampus rs 0.12 -0.14 0.10 
p 0.65 0.59 0.73 
d.f. 15 15 12 
Right Hippocampus rs 0.20 -0.24 -0.24 
p 0.43 0.34 0.39 
d.f. 16 16 13 
Gray Matter rs 0.04 -0.10 -0.32 
p 0.89 0.71 0.27 
d.f. 15 15 12 
 
 
Brain Region Object place Distance 
Cerebral Blood Flow 
Frontal Lobe r -0.575 
 p 0.04   d.f. 11 
Occipital Lobe r -0.521 
 p 0.068   d.f. 11 
Parietal Lobe r -0.689 
 p 0.009   d.f. 11 
Temporal Lobe r -0.47 
 p 0.105   d.f. 11 
 
 
 
 
 
 
Table 15: Correlations between CBF and CVR and behavioral measures from the object/place 
memory task. There was a significant correlation between distance from target and gray matter 
CBF. 
Table 16: Correlations between Object Place Distance and CBF broken down by brain region. 
There is a significant correlation between object place distance and CBF in the frontal lobe and 
parietal lobe. 
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   Response to Lure Accuracy Pattern 
Separation 
Pattern 
Completion    “Old” “Similar” 
Cerebral Blood 
Flow 
Left 
Hippocampus 
rs 0.02 0.03 0.18 0.29 0.15 
p 0.93 0.92 0.45 0.22 0.53 
d.f. 18 18 17 18 18 
Right 
Hippocampus 
rs 0.10 -0.05 0.16 0.22 0.21 
p 0.69 0.83 0.52 0.35 0.38 
d.f. 18 18 17 18 18 
Gray Matter rs 0.15 0.16 0.12 0.13 0.16 
p 0.54 0.52 0.63 0.59 0.51 
d.f. 17 17 17 17 17 
Cerebrovascular 
Reactivity 
Left 
Hippocampus 
rs 0.00 0.12 -0.28 -0.05 0.09 
p 0.99 0.62 0.27 0.84 0.73 
d.f. 16 16 16 16 16 
Right 
Hippocampus 
rs 0.07 0.12 -0.22 -0.17 0.13 
p 0.77 0.62 0.36 0.49 0.60 
d.f. 17 17 17 17 17 
Gray Matter rs -0.03 0.23 -0.14 -0.01 0.05 
p 0.90 0.36 0.58 0.97 0.84 
d.f. 16 16 16 16 16 
 
  
Table 17: Correlations between CBF and CVR and behavioral measures from the pattern 
separation task. No significant correlations were found. 
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Discussion 
 
After correcting for age, several correlations were found between cognition and neurovascular 
function.  
 
At Risk Subjects 
When only the subjects at risk for AD were analyzed, relationships between CVR and cognition 
were discovered. There was a significant positive correlation found between the within between 
ratio when viewing face stimuli and CVR in the gray matter. When the gray matter trend was 
further explored, there was not a specific brain region that was significantly driving this trend, 
although there was a trend toward a negative correlation between the occipital lobe and face 
within between ratio and a positive correlation between the parietal lobe and face within between 
ratio. Additionally, CVR in the left hippocampus was associated with decreased face/name 
memory. Finally, right hippocampus CVR and gray matter CVR was negatively correlated with 
distance to the target and positively correlated with accuracy in the object/place memory task. 
When the gray matter trend was analyzed further, there again was not a specific brain region that 
was significantly driving the trend, although there was a trend toward a correlation between 
accuracy and CVR in the parietal lobe.  No significant correlations were found between CBF and 
any cognitive measure.  
 
Previous studies have indicated that CVR declines more rapidly than CBF during aging143, and 
our group hypothesized that CVR would be decreased in the at risk group compared to the 
control group. While we did not see a group difference in CVR (see Chapter IV), it is interesting 
that we found correlations between CVR and cognition in the at risk group.  
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The within-between ratio of the oddity detection task is an indirect method for determining how 
many features of a complex object a person can hold in his or her memory at a time. A higher 
number means that more features can be held. We found that the within between ratio for face 
stimuli is associated with increased CVR throughout the brain. The oddity detection task is 
reliant on the perirhinal cortex, but processing face stimuli also involves the complex interplay of 
several brain structures including the occipital face area and the fusiform face area151,152. To 
further determine if one specific brain region was driving this trend, the brain was further 
segmented into brain lobes. It was found that there was a positive correlation between CVR in 
the parietal lobe and face within between ratio. Surprisingly, there was a trend toward a negative 
correlation between face within between ratio and CVR in the occipital lobe.   
 
Higher CVR in the right hippocampus correlated with better performance on the object/place 
memory task. The right hippocampus has been associated with spatial processing153,154, so it 
would make sense that CVR in that specific brain region would correlate with a test of spatial 
memory. Further, higher CVR in total gray matter was associated with better performance on this 
task. When gray matter was divided into brain lobes, there were no significant correlations found 
between any specific brain lobe and performance in this task, meaning perhaps it is increased 
CVR in general and not in any specific cortical area that is driving increased accuracy in this 
task. 
 
Interestingly, we found a negative correlation between face/name memory and left hippocampal 
CVR. Whereas the oddity detection task required complex visual processing of a face, the 
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face/name memory task required binding an image of a face to an arbitrary name in memory. 
The left hippocampus is associated with object naming155 and verbal memory153,156, and left 
anterior temporal lobe damage is associated with an inability to retrieve proper names157. During 
the encoding portion of this task subjects are shown a number of faces and names, and the 
retrieval portion is a forced-choice task between two possible names. Perhaps the increased CVR 
in the left hippocampus results in either inefficient encoding, or a false memory for the wrong 
name during retrieval.  
 
If blood vessels are unable to dilate in response to a stimulus, brain tissue may become 
hypoperfused and mildly ischemic. Hippocampal subfields have been shown to be particularly 
sensitive to ischemic injury158. CVR is an index of vessel dilatory capacity, and these results 
indicate that a reduced dilatory capacity is correlated with decreased cognitive ability. We have 
no current way of knowing which subjects in our at risk group will go on to develop the disease, 
however one might predict that the subjects that currently have lower CVR and lower 
performance on the cognitive tasks may be at an even higher risk for AD.  
 
Control Subjects 
The control subjects demonstrated significant correlations between CBF and cognition, but no 
correlations between CVR and cognition.  There was a positive correlation between gray matter 
CBF and face/name memory, a negative relationship between gray matter CBF and distance 
from the target in object/place memory, and a positive relationship between gray matter CBF and 
accuracy in object/place memory.  
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All of the significant correlations found in the control subjects indicate that gray matter CBF is 
associated with better performance in the cognitive test. This fits with other studies that have 
demonstrated a relationship between CBF and cognition159,160. When gray matter CBF was 
broken down by brain lobe, many of the correlations remained significant. Or approached 
significance, indicating that it may be a global increase in CBF that is driving increased accuracy 
in the cognitive tasks.  
 
Higher CBF typically means better vascular function, and a higher availability of oxygen and 
glucose for neurons. It is logical that increased CBF would be associated with a better cognitive 
performance.  
 
It is interesting that CBF correlates with cognition in control subjects, but not in at risk subjects. 
CBF has been shown to decline with healthy aging, however Wierenga et. al. have posited that 
there may be a biphasic curve to CBF in the years leading up to an AD diagnosis139. According to 
this theory, CBF first increases to levels higher than controls, then during advanced stages of the 
disease it declines. If there is a biphasic curve that would explain why at risk subjects do not 
have any significant correlations between CBF and cognition, as their CBF may be at different 
levels based on the stage of the disease process that they are in.  
 
Conclusions 
We found that CVR correlates with cognition in at risk subjects but not control subjects, while 
CBF correlates with cognition in control subjects but not at risk subjects. CBF and cognition 
have been shown to decline with age, but the relationship between CBF and AD and how it may 
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influence cognition is unclear. We believe that CVR may be a more powerful predictor of future 
decline than CBF.   
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CHAPTER VI 
CONCLUSIONS AND FUTURE DIRECTIONS 
Summary of Findings 
Alzheimer’s disease (AD) is the most common form of dementia, and it is a tremendous public 
health concern. One potential way to better understand AD is to identify the earliest possible 
changes that may occur in the beginning stages of pathogenesis. For this study we aimed to 
identify any differences already present in middle-aged adults at risk for Alzheimer’s disease due 
to a first degree family history.  
 
We first examined the performance of at risk subjects on cognitive tasks designed to target the 
areas of the brain first impacted by AD pathology. We found that there were differences between 
subject groups in the oddity detection and face/name memory tasks, which were designed to 
target the perirhinal and CA1 regions of the hippocampus, respectively. This demonstrates that 
even in cognitively normal and otherwise healthy subjects very subtle cognitive changes are 
potentially occurring and are able to be identified in our small sample of subjects.  
 
Next, we sought to determine if there were any neurovascular or volumetric differences between 
at risk subjects and controls using novel neuroimaging techniques. We did not find any 
differences between groups, which indicates that there are either no changes in neurovasculature 
at the stage that we were studying, or that the specific sequences that we used were not sensitive 
enough to detect subtle differences.  
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Finally, we wished to determine if there were any correlations between cognition and 
neuroimaging, and how those relationships were different in the at risk group compared to the 
control group. We found that there were several cognitive measures in the at risk group that 
correlated with cerebrovascular reactivity, but none of the cognitive tests correlated with cerebral 
blood flow. In the control group, we found the opposite pattern. Cognitive tests correlated with 
cerebral blood flow, but not cerebrovascular reactivity. 
 
Together, these results indicate that subjects at risk for AD have subtle but detectible cognitive 
changes compared to age-matched controls.  
 
Future Directions 
 
The biggest caveat to this study is its cross sectional nature. The best way to truly understand the 
results would be to follow the subjects used in this study longitudinally with repeated testing, and 
eventually to identify the subjects who develop AD. We also do not have knowledge of which 
subjects will develop AD in the future, and thus cannot interpret the predictability of these tasks.  
 
Since we believe that the cognitive differences may be tau-driven, it would also be interesting to 
add a tau detection component, either using the newly developed PET ligands, through CSF 
testing. We could also add more testing to bring this study in line with the protocols used in other 
major longitudinal studies, such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI, 
protocol available at: http://www.adni-info.org/Scientists/ADNIStudyProcedures.html). 
 
Although we found a significant difference between study groups in the cognitive testing, there 
are ways that we could improve the sensitivity of these tests and learn more about the 
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physiological processes underlying these differences. For the oddity detection task, the feature 
ambiguity of the visual stimuli could be varied across real-world objects and Greebles so that we 
can determine whether feature ambiguity or the novelty to the Greeble stimuli is the driver of the 
difference. The object/place memory test found no difference between the at risk and control 
groups, however this test could be made more ecologically valid by implementing it in a virtual 
reality system rather than on a two-dimensional screen. The results of the pattern separation task 
could be better understood by adding eye-tracking to determine if the trend in pattern completion 
was due to impaired encoding, or retrieval processes. It would also be interesting to determine if 
training in any of these cognitive tests would be protective against future decline.  
 
We did not see any differences in structural or neurovascular imaging. We believe that this is a 
true finding and not a result of the study being underpowered. To confirm this, we performed a 
power analysis using the actual data from this study (Table 18), and found that the number of 
subjects required to achieve significance would be unreasonable for this type of study. There are 
constantly new advances being made in neuroimaging. Perhaps with a higher spatial resolution, 
or a higher signal to noise ratio the neurovascular measurements could be more sensitive and 
show a difference between subject groups. If there are truly no differences between groups in 
neurovascular function at this stage, that increases the validity of fMRI studies that attribute the 
BOLD response to changes purely to neural activation. An fMRI component could be added to 
the cognitive tests to determine if there are changes in the pattern of neural activation in subjects 
at risk for AD.  
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ROI	 At	Risk	Mean	 Control	Mean	 Average	Standard	Deviation	 Required	N	 Effect	Size	
Left	Hippocampus	CVR	 0.016	 0.022	 0.014	 752	 0.435	
Right	Hippocampus	CVR	 0.017	 0.021	 0.016	 536	 0.243	
Gray	Matter	CVR	 0.024	 0.024	 0.008	 53166	 0.024	
Left	Hippocampus	CBF	 28.34	 28.59	 5.97	 19154	 0.040	
Right	Hippocampus	CBF	 28.94	 28.27	 5.78	 2334	 0.116	
Gray	Matter	CBF	 31.49	 30.14	 5.53	 532	 0.244	
 
The correlations that we found between neurovascular imaging markers and cognitive testing 
indicate that perhaps CBF may have a stronger influence on cognitive processes in normal aging, 
but CVR may have an influence on cognitive processes in the early stages of AD. To better 
understand these influences, it would be interesting to divide the at risk group into people with 
high CVR and people with low CVR and track them over time. Our hypothesis would be that 
those with lower CVR would be at an even higher risk for the development of AD. The 
correlative analysis was not corrected for multiple comparisons, because we believed that this 
might result in too many Type II errors (false negatives). If they had been corrected, the 
statistical tests would not have reached significance. Many studies that look at human data, 
particularly studies that combine physiology and cognition, have large cohorts of subjects to 
maximize statistical power. While the number of subjects used in this study were comparable to 
purely cognitive studies and purely imaging studies, we lacked to statistical power to thoroughly 
investigate the relationship between these two factors.  In the future, an increase in the number of 
subjects would likely improve the interpretability of this result.  
 
Table 18: Power analysis of neurovascular imaging. Significance was set at 0.05 and power was set 
at 0.8. 
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This study did not suffer from any issues in recruiting subjects, and many of the subjects that 
were in the study have expressed an interest in returning in the future for further studies. I 
believe that it would be feasible to accomplish many of the directions listed above.  
 
 
Broad Implications 
 
AD is the most common form of dementia, and it is becoming increasingly common as the 
population of the industrialized world ages. There are no treatments that have been shown to 
delay or prevent the onset of AD, and currently there is no cure. The best way to develop a 
treatment for AD would be to better understand the earliest physiological changes that are 
occurring in the disease.  
 
Unfortunately, the earliest stages of AD are not well characterized. A figure developed by Jack 
et. al.161 (figure 16A) is often used to show the field’s best understanding of the timeline of early 
events in AD. The figure illustrates changes in brain structure, often measured volumetrically, 
preceding changes in memory or clinical function. We have updated the Jack figure (Figure 16B) 
to include our hypotheses for the order of events in early AD.  
 
This study has demonstrated that changes in cognition are detectible prior to changes in brain 
structure. These cognitive changes correspond to the route of tau accumulation in the medial 
temporal lobe, indicating that they may be tau-driven.  
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While the figure did not originally include neurovascular imaging, we have also shown that 
cognitive changes are detectable prior to neurovascular changes using our methods. Since CVR 
correlates with several cognitive tests in the at risk group, perhaps CVR changes are occurring 
around the same time but our tests are not sensitive enough to detect this change at the group 
level.   
 
CBF does not correlate with cognition in the at risk group. Based on the Weirenga model of CBF 
changes during AD, we believe that early in life people at risk for AD may have increased CBF, 
but in this age group CBF may be transitioning from being higher than controls to being lower 
than controls. This process is not well understood, and difficult to model, therefore we did not 
include it in our updated figure.  
 
Altogether, this study has expanded our knowledge of the earliest physiological changes that 
occur in AD, and may provide a clearer picture of the order of events.  
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Figure 16: Modified timeline of symptom development during the course of AD. A: Original 
figure from the Jack 2010 paper. B: updated figure to reflect the results of this study. MTL 
specific cognitive function declines after tau, but before volume changes. CVR changes are 
likely occurring around the same time, and CBF changes occur after CVR changes but prior 
to volumetric changes.  
A 
---  MTL Cognitive Function 
---  Cerebrovascular Reactivity 
B 
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